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This work seeks to develop reliable biomarkers of disease activity, 
progression and outcomes through the identification of significant 
associations between high-throughput flow cytometry data and a 
scleroderma clinical phenotype – initially, interstitial lung disease (ILD) - 
which is the leading cause of morbidity and mortality in Systemic Sclerosis 
(SSc). A specific aim of the work involves developing a clinically useful 
screening tool (hereafter a filter). Such a filter could yield accurate 
assessments of disease state such as the risk or presence of SSc-ILD, the 
activity of lung involvement and the possibility to respond to therapeutic 
intervention. Ultimately this instrument should facilitate a refined 
stratification of SSc patients into clinically relevant subsets at the time of 
diagnosis and subsequently during the course of the disease, preventing bad 
outcomes from disease progression or unnecessary treatment side effects. 
This role could involve a scenario in which an SSc patient passes the 
presumptive (FVCstpp) test for ILD, but the filter indicates that their flow 
cytometry (FC) profile is consistent with ILD. In such a case, a physician 
might: 1) increase frequency of testing to detect early development of ILD; 2) 
implement more sophisticated diagnostic procedures (e.g., high resolution 
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chest CT scan - HRCT) to confirm the presence of ILD; and 3) consider 
prophylactic disease modifying treatments. Note that the intention of this 
research is not to develop screening tools that merely aim at predictive 
accuracy, but to produce methods that also contribute to the understanding 
of disease mechanisms. Having used ILD as phenotype, subsequent analyses 
in this thesis used different phenotypes: antiTopoisomerase (ATA), 
antiCentromere Anti Nuclear Antibodies (these antibodies are most strongly 
associated with diffuse and limited systemic sclerosis respectively) and 
cancer. This research was based on clinical and peripheral blood flow 
cytometry data (Immune Response In Scleroderma, IRIS) from consented 
patients followed at the Johns Hopkins Scleroderma Center.  
Methods. The methods utilized in the work involve: (1) data mining 
(Conditional Random Forests - CRF) to identify subsets of FC variables that 
are highly effective in classifying ILD patients; (2) Gene Set Enrichment 
Analysis (GSEA) to further refine FC subsets; (3) stochastic simulation and 
Classification and Regression Trees (CART) to design, test and validate ILD 
filters; and (4) Stepwise Generalized Linear Model (GLM) regression and 
Drop-in-Deviance testing to identify minimal size, best performing models 
for predicting ILD status from both FC and selected clinical variables.  
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Results. IRIS flow cytometry data provides useful information in 
assessing the ILD status of SSc patients. Our hybrid analysis approach 
proved successful in predicting SSc patient ILD status with a high degree of 
success (out-of-sample > 82%; training data set 79 patients, validation data 
set 40 patients). Pre-partitioning patients into groups using CART 
significantly increased validation performance to 95% successful ILD 
identification.  When the phenotype was Cancer, FC subsets, created through 
ranked Student t Test scores and point-wise GLM were statistically 
significant (p < 0.05) using GSEA. After applying Stepwise GLM on the 
CRF FC subsets, four FC variables were observed to be highly associated 
with Cancer in SSc patients.  An ILD-Cancer GSEA intercomparison was 
made (use the best ILD FC set with cancer as the phenotype, and vice-versa) 
showed that GSEA results were highly phenotype-specific. Other 
phenotypes including ATA and ACA were also analyzed and found to be 
statistically significantly associated with certain subset of FC variables, but 
with different FC set sizes (38 and 6 respectively) based on the CRF-GSEA-
Stepwise GLM algorithm.  
In future research, HRCT confirmation of patient ILD status will be a 
critical next step in developing additional confidence with our approach (and 
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Interstitial lung disease (ILD) is a major 
cause of death in SSc patients. In ILD, 
sections of lung tissue become hardened 
and scarred and thus lose function. Lung 
transplantation is often not an option for 
patients with severe ILD (De Cruz & Ross, 
2013). 
A. INTRODUCTION 
A.1 Systemic Sclerosis 
Systemic Sclerosis is an autoimmune disorder - it is “a condition that 
occurs when the immune system mistakenly attacks and destroys healthy 
body tissue” (Goronzy & Weyand, 2007; Siegel & Lipsky, 2009). SSc can 
have severe effects, principal among them extensive fibrosis, vascular 
alterations and autoantibody response (Gabrielli, Avvedimento & Krieg, 
2009; Boin & Rosen, 2007). SSc 
is classified into limited and 
diffuse forms depending on the 
extent of skin involvement. Both 
subsets can manifest progression to visceral organ involvement, e.g., lungs, 
heart, gastrointestinal tract and kidneys (Harris & Rosen, 2003). Although 
this type of classification identifies distinct clinical phenotypes, it remains 
inadequate to fully capture the spectrum and heterogeneity of SSc clinical 
manifestations (Gabrielli, Avvedimento & Krieg, 2009). Limited cutaneous 
SSc often manifests as CREST Syndrome (Calcinosis, Raynaud's 
phenomenon, Esophageal dysfunction, Sclerodactyly and Telangiectasias; 
Winterbauer, 1964). Both SSc types can become life-threatening, 
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particularly pulmonary fibrosis (or Interstitial Lung Disease, ILD) which is 
an important cause of morbidity and frequent cause of death in SSc patients 
(Steen, 1998). The essential nature of ILD is: “the majority of SSc-ILD 
patients show replacement of the normal lung parenchyma with inflamed 
and fibrotic tissue, which is ineffective for gas exchange” (Luo & Xiao 2011; 
Harrison et al. 1990). Additionally, SSc patients are more susceptible than 
the general population to other severe diseases including a variety of 
malignancies (Shah & Rosen, 2011).  
As is the case with other autoimmune disorders, there are no curative 
therapies but only treatments aimed at halting progression towards end-stage 
disease. Due to limited knowledge about the role of autoimmunity in the 
pathogenesis of SSc, conventional treatments such as anti-inflammatory and 
immunosuppressant therapies are typically poorly effective (Boin & Rosen, 
2007). 
There are three main obstacles preventing a full understanding of SSc 
and the development of effective targeted therapies. First, there is extreme 
heterogeneity in clinical manifestations among different SSc patients. The 
disease course is highly variable in terms of onset, timing, intensity of 
symptoms, patterns of organ involvement and response to therapy. It has 
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been suggested that susceptibility to SSc varies in accordance with certain 
demographic factors such as gender, race and age (Chifflot et al., 2008). For 
example, high female-to-male ratios were consistently reported, with males 
developing in general more severe disease. Non-Caucasian patients and in 
particular African Americans tend to have an earlier onset of SSc, a more 
aggressive clinical course and higher mortality (Gelber et al. 2013). 
Schachna et al. (2003) identified “increasing age at scleroderma onset as a 
risk factor for pulmonary arterial hypertension (PAH)” and Perez-
Bocanegra et al. (2010) discovered that there exist “differences in SSc 
clinical features and survival” for different age groups.  
The second major challenge derives from the occult nature of early 
immune effector’s pathways and the complex interaction of multiple 
humoral or cellular mediators, making the identification of the key drivers of 
clinical phenotypes difficult. Subsumed within this challenge is the difficulty 
in measuring and characterizing immune response (Whitfield et al. 2003; 
Chung and Utz 2004; Warrington et al. 2006; Boin et al. 2008; Salamunić 
2010). Several levels of evidence support the involvement of the immune 
system, particularly during early stages of SSc or at the time of disease 
activity within specific target tissues (e.g., lungs). Nonetheless, the 
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relationship between a sustained immune response and the progression 
toward different clinical outcomes remains poorly understood. In addition, 
despite convincing in-vitro data linking innate and adaptive immunity to 
aberrant collagen synthesis and endothelial cell dysfunction, no reliable and 
accurate measure of the ongoing immune response has been defined in-vivo 
in SSc patients (Salamunić 2010; Boin et al. 2008; Cracowski et al. 2001).  
Pathologic studies on SSc patients with early lung disease showed that 
fibrosis is preceded by the presence of a mixed interstitial inflammatory 
infiltrate spilling into the alveolar spaces (alveolitis) composed mainly of 
macrophages, lymphocytes (notably T cells), granulocytes and other 
accessory cells (Harrison et al. 1990). As the disease progresses, deposition 
of collagen and thickened alveolar walls substitute air spaces with less 
evidence of inflammation. It is plausible that with early detection and 
treatment of lung inflammation, SSc patients may avoid progression to 
severe pulmonary fibrosis (Varga, 2014). T lymphocytes seem to have a 
central role and are required for initiation and propagation of the fibrotic 
lung insult. In SSc patients with alveolitis, T cell counts are increased in the 
pulmonary interstitium on lung biopsies and in Bronchoalveolar lavage 
(BAL) fluids. CD8+ T cells with an activated phenotype predominate and 
correlate with more severe pulmonary fibrosis (Yamadori et al. 2000; Luzina 
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This thesis will therefore concentrate 
on different subsets of T cells. 
et al. 2003). Previous studies have shown that increased frequency of 
circulating T cells exhibiting a “polarized” phenotype (i.e., T cells 
manifesting specific patterns of cytokine secretion) are significantly 
associated in SSc patients with the presence of pulmonary fibrosis and lung 
disease progression (Boin et al 2008; Truchetet et al. 2010). Despite all this 
evidence, it remains unclear how T cells contribute with their unique 
features and function to the pathogenesis of SSc at different times along 
disease progression, which is the third obstacle in understanding SSc. 
Elucidating the close temporal as well as biological relationship that exists 
between abnormal immune activation and the clinical manifestations present 
in SSc may allow for identification of 
novel and specific cellular as well as 
molecular probes to monitor disease activity, predict with accuracy clinical 
outcomes and ultimately design novel disease-specific therapeutic strategies. 
Potential participants in SSc pathogenesis include: (1) auto-antigens 
(Rosen & Casciola-Rosen, 1999, 2009; Casciola-Rosen, Anhalt & Rosen, 
1994); (2) antigen presenting cells (APCs) (Leon et al., 2000; Alexander & 
Wahl, 2011); (3) Interleukin 2 (IL-2) (Burroughs et al., 2006, 2008; Isaeva 
& Osipove, 2009a,b); (4) Type I interferon (Hall & Rosen, 2010);  (5) T 
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lymphocytes or T cells (Leon et al., 2000, 2004; Chao, et al., 2004; 
Burroughs et al., 2006, 2008; Carneiro et al., 2005, 2007; Isaeva & Osipove, 
2008; Baltcheva, 2010; Alexander & Wahl, 2011; Velez de Mendizabal et 
al., 2011; and Saeki & Iwasa, 2009, 2010). A possible mechanism for 
autoimmunity is shown in Figure A-1 which illustrates a series of 
interrelated biological events. 
 
Figure A-1. A Possible Mechanism for Autoimmunity  
Source: Hall & Rosen, 2010. 
After plasmacytoid Dendritic Cells (pDCs) recognize virus in the 
form of nucleic acid in apoptotic debris, a large amount of type I IFN is 
rapidly produced in response, which triggers three processes: (1) “self-
amplification of the Toll Like Receptor (TLR) pathway in pDCs”; (2) the 
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state of the target cells becomes antiviral; and (3) monocytes are 
differentiated and Dendritic Cells (DCs) activated. DCs will “process and 
present self and viral antigens derived from dying cells” and activate 
autoreactive CD4+ and CD8+ T cells for which survival would be promoted 
by type I IFN receptor signals. These signals also “enhance the cytotoxic 
activity of Cytotoxic T Lymphocytes (CTLs) which eliminate uninfected host 
cells, expressing large quantities of autoantigens via the granzyme B 
pathway”. Remnants of dying cells are consumed by DCs and “presented for 
recognition by T cells in a self-amplifying loop” (Hall & Rosen, 2010).  
A.2 Literature Review - Methods 
Different quantitative approaches have been used to investigate SSc 
for purposes of prediction and explanation.  In particular, various methods 
have been applied in order to: 1. better understand the mechanism of 
systemic autoimmunity in general; 2. provide improved insights concerning 
the SSc patients population in terms of epidemiological characteristics; 3. 
identify association between certain biomarkers and clinical manifestation or 
measurements of SSc; and 4. make predictions of disease outcomes. 
Examples of each are summarized in the literature review of this thesis. 
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They fall into two major categories: mechanistic modeling and data-based 
(or data-driven) analysis.  
A.2-1 Mechanistic Models 
Although the pathogenesis of SSc is not yet fully known, it has been 
suggested that all systemic autoimmune diseases may share common 
underlying mechanisms (Wahren-Herlenius & Dorner, 2012).  Most 
mechanistic models of autoimmunity are built using ordinary differential 
equations. Waniewski and Waniewski & Prikrylova (1988) mathematically 
described autotolerance and autoimmunity considering the effect of 
plasmapheresis and immunosuppression. Nevo et al. (2004) presented a 
spatio-temporal model based on the concept of “comprehensive immunity” 
which views autoimmunity as a “special case” of immunity. They suggested 
that autoimmunity provides a protective mechanism for the Central Nervous 
System (CNS), e.g., preventing the CNS from degenerating into a more 
chaotic state. Leon et al. (2000, 2004) proposed a cross-regulation model 
that implies a “bi-stable” state – autoimmunity or tolerance – a state in 
which effector T cells and regulatory T cells coexist in a balanced manner. It 
was argued that there exist tradeoffs between the risk of autoimmunity and 
reactivity of the system. The role of Antigen Presenting Cells (APC) was 
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emphasized in the interaction between cytotoxic T cells and regulatory T 
cells. Burroughs et al. (2006) argued that cytokines such as IL-2 are actively 
involved in autoimmunity and therefore should be included in mathematical 
models.  Leon & Garcıa-Martınez (2011) explicitly include IL-2 into their 
cross-regulation model. Iwami et al. (2007) developed a mathematical model 
based on a personal immune response function and a target cell growth 
function. Alexander and Wahl (2011) emphasized the importance of 
including professional1 APC in modeling the mechanism of autoimmune 
diseases, which is consistent with the theory offered by Hall & Rosen (2010) 
on the self-amplifying nature of type I IFN production and tissue damage in 
systemic autoimmunity. Velez de Mendizabal et al. (2011) used the T cell 
cross-regulation model to analyze the “relapsing-remitting dynamics” of 
Multiple Sclerosis. Saeki & Iwasa (2009, 2010) used a fitness function to 
explain “the advantage of having regulatory T cells” and identified an 
optimal number of regulator T cells.  
                                                 
1 Professional Antigen Presenting Cells are APC that produce a co-stimulatory signal that 
activates T cells. In our case, the co-stimulatory molecule is MHC II (Major Histocompatibility 




A.2-2 Data-Driven Models 
Traditional approaches for analyzing SSc integrate data from 
biological measurements, physician insight, clinical experience and other 
sources and thus are not purely data driven (Mathai et al., 2010; Mathian et 
al., 2012). Data-driven analysis has gradually entered the arena of 
autoimmunity research including SSc. Statistical methods have been applied 
to three levels of data: population, genetic and cellular. At the population 
level, the European League Against Rheumatism (EULAR) Scleroderma 
Trials And Research (EUSTAR) group collected the “Minimal Essential 
Data Set” (MEDS) with 3656 SSc patients from 102 centers and 30 
countries (Distlar et al. 2009). They found that the association between 
autoantibody status and clinical manifestations of SSc was stronger than that 
between autoantibody and SSc subtypes (diffuse vs. limited) on a cross-
sectional multivariate analysis. EUSTAR (2013) also concluded that 
“pulmonary fibrosis, PAH and cardiac causes, accounted for the majority of 
deaths in SSc” based on 5860 SSc patients. Another interdisciplinary registry 
of 1483 patients in Germany was established to better detect SSc patients 
with various disease manifestations (Hunzelmann et al., 2008). Recently, 
Merkel et al. (2012) performed an individual patient meta-analysis based on 
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Data driven research analyses on 
Scleroderma are fairly recent. SSc 
data driven analysis using flow 
cytometry data is novel. 
629 diffuse SSc patients. Razykov et al. (2013) identified “the association 
between sociodemographic and clinical variables and pruritus” using 
multiple logistic regression based on 959 patients. Pruritus was determined 
to be statistically associated with “the degree of skin involvement and 
gastrointestinal system involvement”. 
Microarray data has been a major focus of SSc analysis on a genetic 
level. Symbolic Discriminant 
Analysis was used to make 
classifications and predictions of 
autoimmune disease using DNA gene expression data collected in peripheral 
blood mononuclear cells (PBMC) from 12 control individuals and 16 
patients with either rheumatoid arthritis (RA) or systemic lupus 
erythematosus (SLE) (Moore et al., 2002). Gene expressions of skin biopsies 
from four diffuse SSc patients and four normal volunteers were analyzed 
using hierarchical clustering (Whitfield et al., 2003) while genetic 
programming, an extension of genetic algorithms, was employed to identify 
“differences in patterns of gene expression of skin biopsies” from control 
and case groups of SSc patients (Paul & Iba, 2006). Microarray data of a 
molecular phenotype (combined proteome and transcriptome) from non-
obese diabetic (NOD) mice was used to explore pathways of autoimmune 
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diabetes using two-way analysis of variance (ANOVA), k-mean clustering 
and principal component analysis (PCA) (Gerling et al., 2006). Duan et al. 
(2008) analyzed the gene expression of purified monocytes and T 
lymphocytes from 18 female SSc patients and 11 healthy female control 
subjects in an attempt to gain insights into the pathogenetic mechanisms of 
SSc. They suggested that “leukocytes respond to cytokine [messenger RNA 
(mRNA)] locally in the vessels”. Lindahl et al. (2013) identified “a strongly 
suppressed interferon-stimulated gene program in fibroblasts from fibrotic 
lung” using microarray profiling.  
Advanced techniques for acquiring data on a cellular level include: 
enzyme-linked immunosorbent assay (ELISA) which uses antibodies and 
color change to identify different entities (Ashihara et al., 2011); MACS 
MicroBeads Column (Miltenyi Biotec, 2014) which is a type of cell 
separation and culturing method; and flow cytometry (§B.1). In order to 
examine the association between PAH biomarkers, IFN-regulated gene 
expression and “alternative activation pathways of SSc”, Christmann et al. 
(2011) analyzed: (1) experimental data of Peripheral Blood Mononuclear 
Cells (PBMCs) isolated using a MACS MicroBeads Column (Miltenyi 
Biotec, 2014); (2) microarray data of IFN-regulated and “PAH biomarker” 
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genes; (3) plasma measurement of Interleukin-13 (IL-13); and (4) IL-4 
concentrations and flow cytometry data of CD14 and other cells. Rank 
correlation (Spearman’s coefficient) and the paired Wilcoxon signed ranks 
test were also used to analyze flow cytometry data of Treg cells and ELISA 
measurement of TGF-β and IL-10 respectively to evaluate the role of Treg 
cells in SSc patients. Linear regression was applied to investigate the 
relations between severity score and activity index of SSc and case-control 
ratio of Treg cell count (Slobodin et al., 2010).  
A review of the literature showed that few studies investigating SSc 
pathogenesis have been solely driven by quantitative data. A study on how 
certain SSc clinical phenotypes are associated with a group of cellular level 
biomarkers purely based on quantitative analysis can be useful in further 
understanding SSc mechanisms. This research therefore mainly addresses 
the quantitative association between certain SSc phenotypes and group of 
FC variable as a whole, namely FC set, and examines the clinical utility of 
the identified FC set based on statistical analyses.  
A.3 Dissertation Outline 
There are six more chapters after the Introduction in this dissertation. 
Chapter B provides detailed description of the flow cytometry and the IRIS 
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data set. Chapter C illustrates the main methodologies used. Chapter D 
presents results associated with different approaches and phenotypes. 
Chapter E includes discussions of the results, followed by conclusions 




B.1 Flow Cytometry 
Flow cytometry (FC) is a powerful tool used to analyze multiple 
characteristics of individual cells within heterogeneous populations (Shapiro, 
2003; Picot et al., 2012). 
Through more than seven 
decades of innovation 
(Perfetto et al., 2004; Picot et 
al., 2012) flow cytometry has 
proven to be exceedingly 
useful in biological and 
medical studies, especially in 
the field of immunology 
(Hedley et al., 1983; Nicoletti 
et al., 1991; Vermes et al., 
2000; Raja et al., 2013). 
The sequence of processes that constitute flow cytometry is shown in Figure 
B-1. 
Figure B-1. Flow Cytometry Processes Sequence 
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As shown below in Figure B-2, flow cytometer instruments have the 
following components: (1) the fluidics system; (2) laser; (3) optics; (4) 
detectors; and (5) the electronics and computer system. The fluidics system 
aligns cells (one at a time) using hydro-dynamic focusing (Lee et al., 2001). 
Individual cells are then excited with a laser beam that causes either forward 
or side scatter. The scattered light from each cell is then directed by optics to 
detectors that generate signals. A dedicated computing system then analyzes 

















B.2 JHU Data Set 
The data set used in this work (Immune Response In Scleroderma, 
IRIS, 2013) was provided by the Division of Rheumatology of the JHU 
School of Medicine. It is based on anonymous human subjects. Currently 
there are 158 SSc patients in total and each has 190 features grouped 
according to: 1. general background knowledge, e.g., age, sex and race; 2. 
clinical data such as presence of lung disease and skin severity score; 3. 
serology that indicates the presence and type of autoantibodies; 4. 
pulmonary function tests; 5. echocardiograms; 6. medications; and 7. T cell 
flow cytometry data.  
The original 116 T cell flow cytometry variables2 contained in the 
data set fall into 4 functional panels: memory, activation, polarization and 
traffic (data in this panel are particularly pertinent to skin and lung T cell 
migration). Each functional panel has different T cell subsets that are 
connected to each other through a hierarchical structure. An example of the 
memory panel is given in Figure B-3.  All of the child nodes are expressed 
as percent of the parent node. Specific biological definitions of each 
acronym in the figure can be found in Table B-1. 
                                                 




This IRIS data set has been occasionally updated at times which is a 
normal course of events as procedures (gating) are refined, new patients are 
added and additional blood testing performed. Six versions of the data set 
exist so far, labelled by their dates: Jun. 21st, 2012, Aug. 2nd, 2012, Jan. 
29th, 2013, Feb. 14th, 2013, Jul. 18th, 2013 and Mar. 8th, 2013. The version 
of the data set will be denoted below as IRISMMDDYY, e.g., IRIS071813 
means data set updated on Jul. 18th, 2013. Although results based on 
different data sets can differ, these differences have consistently been 
inconsequential. 
The hierarchical structure and FC variable definitions for the 




Figure B-3. Memory Panel Hierarchy 
Source: Dr. Andrea Fava, Division of Rheumatology, JHMI 














Table B-1 Memory Panel T cell Subset Definitions 
Code Subset Definition 
mem3abs CD3+ absolute count 
mem4 CD3+/CD4+/CD8- 
mem8 CD3+/CD4-/CD8+ 
memratio48 ratio of mem4 to mem8 
naive4 CD3+/CD4+/CD8-/CD8-/CD45RA+/CCR7+/CD27+/CD28+ 
(Naïve T cells) 
cm4 CD3+/CD4+/CD8-/CD8-/CD45RA-/CCR7+ (Central 
memory) 
emra4 CD3+/CD4+/CD8-/CD8-/CD45RA+/CCR7- (Terminally 
differentiated "effector memory CD45RA+" cells) 


















(Naïve T cells) 
cm8 CD3+/CD4-/CD4-/CD8+/CD45RA-/CCR7+ (Central 
memory) 
emra8 CD3+/CD4-/CD8+/CD45RA+/CCR7- (Terminally 
differentiated "effector memory CD45RA+" cells) 

















In the following sections, several methods are described that all 
essentially have the same purpose: to reduce the dimensionality of the data. 
The presumption made here is basically that not all 116 (or later, 112) flow 
cytometry variables are likely to be useful in either predicting the ILD status 
of SSc patients  or gaining a better understanding of the etiology and 
pathogenesis of systemic sclerosis and its connections to selected 
phenotypes, mostly notably, ILD and cancer. Later, I also performed 
preliminary analyses on other phenotypes including Anti-topoisomerase I 
antibodies (ATA, or anti-Scl-70 antibodies) and anti-centromere antibodies 
(ACA).  
The rest of the chapter starts with introducing the traditional statistical 
approach Principal Component Analysis (PCA) which is well known in 
reducing data dimensionality (§C.2). It was found that the resultant principal 
components cannot be biologically interpreted. Therefore, results of PCA 
were not used for the rest of this research. Next is description of four non-
parametric data mining methods (Classification And Regression Tree, 
Random Forest, Conditional Random Forest and Support Vector Machines) 
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and related model performance evaluation procedures (§C.3).  In Section 
§C.4, I described Gene Set Enrichment Analysis (GSEA) algorithm and how 
it was adapted in this research including its algorithm and permutation test. 
Having identified the best FC subset using data mining methods and GSEA, 
there were two analysis directions – drawing statistical inference and making 
predictions. The former is the combination of Generalized Linear Regression 
Model (GLM) and stepwise variable selection algorithm which will be 
illustrated in Section §C.5. The latter is the randomized filter design 
(introduced in §C.6) which essentially is a screening tool used to 
differentiate SSc patients with ILD from those without. Figure C-1 gives an 
illustration of the relations among the last three methods mentioned. 
 
Figure C-1. Two Analysis Directions  
GSEA
Stepwise GLM Screening Tool 
Stochastic Simulation
(Randomized Screening Tool Design) 
Inputs are FC Profiles; Output is 
patient ILD Status
First Training then Validation





C.2 Principal Component Analysis 
Principal Component Analysis (PCA) is a mathematical procedure 
widely used in reducing data dimensionality without loss of useful 
information from original data set. In specific, PCA will create a set of new 
variables, namely Principal Components, that are linear combinations of the 
original variables (Pearson, 1901; Ramsey & Schafer, 2012). The 
coefficients of the original variables that are associated with each principal 
component are called loadings. Variables have large variance will tend to 
have large loadings (Wold, Esbensen, & Geladi, 1987). The principal 
components are closely related to each other. The first principal component 
will be constructed to have the largest variance and the second principal 
component will be established in the same way with one extra constraint that 
it will be perpendicular to the first one. Other principal components will be 
established similarly. For example, the third principal component will also 
have the largest variance and have to be orthogonal to the plane where the 
first and second principal component locate. All the created principal 
components will therefore be uncorrelated even if the original variables are 
correlated (Wold, Esbensen, & Geladi, 1987; Abdi & Williams, 2010; 
Ramsey & Schafer, 2012). The purpose is to define a few dimensions (the 
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first few PCs) that capture most of the variance, are uncorrelated, and might 
have an interpretation.  Factor analysis (Child, D., 2006) is a set of 
procedures that further manipulates those components (including orthogonal 
and non-orthogonal rotations) in order to increase their interpretability. 
In this research, interpretation of the principal components can be 
difficult in that we found that the linear combinations of FC variables 
unfortunately contained little understandable biological meaning. In the next 
two sections (§C.3 and §C.4), I will present a new method that is 
combination of data mining approach and Gene Set Enrichment Analysis. 
This method can maintain interpretability of the results while reducing data 
dimensionality. In future research, Factor Analysis could be applied with the 
same goal. 
C.3 Data Mining and Partitioning Methods 
Three major schools of statistical and data mining methods have been 
proven useful for medical diagnosis (Kononenko, 2001) including: 1) 
statistical pattern recognition method such as naïve Bayesian Classifiers 
(Domingos & Pazzani, 1997); 2) artificial neural networks (Bishop, 1995); 
and 3) inductive learning of symbolic rules such as the decision trees method  
(Breiman et al., 1984). In that the IRIS data set used in this study is featured 
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by high correlated predictor variables issue, naïve Bayesian Classifiers was 
not used because of its assumption that all the features in the data set of 
interest should be independent.  
Although artificial neural networks can yield high predictive accuracy 
in medical diagnosis (Khan et al., 2001; Dreiseitl  & Ohno-Machado, 2002), 
it has been found that “the network comes to clinical closure based on the 
settings of all variables in a pattern and that the impact of a single variable 
cannot be taken out of the context of a pattern” (Baxt, 1992). Lately, there 
was discovery that neural network may be useful in presenting information 
concerning contribution of each variable for estimating the response 
variables but with the condition that interpretation of model parameters can 
only be verified externally (Olden et al., 2004). This model was not adopted 
in this research because of its limitations in making statistical inference such 
as extracting variable importance information.  
After removing observations whose FC profile was not complete (i.e., 
containing missing values), the number of observations is smaller than the 
number of covariates, resulting in the problem known as “Large P small N”. 
Therefore, only non-parametric methods such as decision trees models were 
considered because parametric approaches tend to overfit the data set. Later, 
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in this research, after the dimensionality of the data set was reduced, 
parametric methods such as logistic regression model were revisited. In this 
section, I will describe the models that were evaluated in this research and 
the criteria used to determine the best model.  
C.3-1 Models Implemented 
Classification And Regression Trees (CART) (Breiman et al., 1984) is 
a modeling approach for classification and regression. Classification refers 
to the situation where the response is binary or categorical. Its regression 
interpretation is used here, that is, using predictor variables (flow cytometry 
expression) to predict a continuous (0,1) response (the probability of having 
ILD or Cancer). CART is a non-parametric procedure (there is no reliance 
upon data distribution) comprised of a sequence of recursive tests, with the 
outcome of a current Test determining the specifics of the next Test and 
terminated by stopping criteria. The first Test is to identify which FC 
variable is most important in accurately predicting ILD status and the value 
of that variable (from among all the values in the data set). There exist 
different metrics for importance depending upon whether CART is used for 
classification or regression. The following equations and corresponding 
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description regarding CART are from (Hastie et al., 2009). The measure of 
node impurity used here is residual sum of squares (RSS): 
( )( )2i iRSS y f x= −∑  
For each SSc patient i (i = 1, 2, ..., N) there are p FC expressions 
( )1 2 ,.. ,, .i i i ipx x x x= and a binary response iy  (ILD status). The FC data are 
partitioned into M regions R1, R2, . . . , RM. Response is modeled as a 
constant in each region  









The best 𝑐𝑚�  is the average of yi in region Rm: 
( )|m i i mc ave y x R= ∈
  
which, from an implementation perspective, is not a helpful result because 
identifying the best binary partition on the basis of minimum sum of squares 
is, in general, computationally infeasible. The recourse is to follow a greedy 
algorithm: Starting with all of the data, a splitting variable j and split point s 
are selected which defines the half-planes 
( ) { } ( ) { }1 2, | , |j jR j s X X s and R j s X X s= ≤ = ≥  




For any choice j and s, the inner minimization is solved by 
( )( ) ( )( )1 1 2 2垐 | , | ,i i i ic ave y x R j s and c ave y x R j s= ∈ = ∈  
 Having found the best split value s for FC variable j, the data are 
partitioned into two regions with the splitting process repeated for each 
region. The process is then repeated for all of the remaining regions. An 
additional complication is how large to grow the tree (equivalently, how 
many splits to perform). A large tree may over-fit the data whereas a small 
tree may fail to capture important structure in the data. The balance between 
these two extremes is achieved through validation (see § D.6). 
 Graphically, this gives rise to a tree-like structure shown below. We 
can see in Figure C-2 that the FC expression act4103 at value 1.525 was 
identified as most important (it is associated with the greatest decrease in 
node impurity).  SSc patients whose act4103 expression is less than 1.525 
are split to the left branch, those with act4013 expression greater than or 
equal to 1.525 are directed to the right. The process is repeated (it is 
recursive) with the next most important variable identified as memem4 at 
value 17.65, and so on.  
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Figure C-2. Graphical Presentation of CART 
Thus, the main elements of CART are (Nisbet et al. 2009): rules for 
splitting data at a node based on the value of one variable; stopping rules for 
deciding when a branch is terminal and can be split no more; and finally, a 
prediction for the target variable in each terminal node. 
The stopping rules involve two considerations: (1) instances where 
subsequent splitting is impossible, i.e., a node contains only one patient or a 
node is pure (all patients are ILD or non-ILD); and (2) a pre-specified 
stopping criterion (our stopping criterion was less than 20 patients in a node, 
which is the default setting in R package “rpart” (Therneau et al., 2014)).  
In comparison with traditional regression, CART has advantageous 
attributes beyond being independent of data distribution:  (1) CART is 
relatively insensitive to outliers in the input variables; (2) Stopping rules can 
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be relaxed to over-fit the data. The training tree can then be pruned back to a 
level that maximizes validation performance; and, (3) CART can re-use 
variables in different parts of the tree and possibly uncover complex 
interdependencies between sets of variables. (Nisbet et al. 2009) 
The Random Forest (RF) modeling approach (Breiman, 2001) 
involves an ensemble of many regression or classification trees. Each tree in 
RF differs from CART in the following respects: 1. random (bootstrap) 
sampling of the original data is used to create training subsets (as opposed to 
using the entire data set); and 2. the splitting variables at each node in a tree 
are randomly chosen from a subset of covariates as opposed to the pool of 
all covariates. The output from an RF model is the average of the 
performance from all of the regression trees generated. (Breiman, 2001) 
The Conditional Random Forest (CRF) modeling approach is similar 
to RF in that it is also an ensemble of trees - but with the following 
modification. The variable selection process is separated from the splitting 
criteria and involves a hypothesis testing procedure. The null global 
hypothesis - all stimulus variables are independent of the response - is tested 
by examining the partial hypotheses that each stimulus variable is 
independent of the response. Only when the null global hypothesis is 
32 
 
rejected does the variable selection process continue. This modification 
enforces the condition that each predictor variable selected as a splitting 
variable in each tree to be strongly associated with response variable through 
hypotheses testing under an unbiased conditional inference framework 
(Hothorn et al., 2006). This process exploits the discriminatory power of 
predictor variables and is especially important with our IRIS data set in 
which numerous covariates within the same panel are highly correlated. The 
Variable Importance Measures (VIMs), quantitative measurements of 
relative importance among predictor covariates, of RF can be unstable and 
suffer from “correlation bias” due to the effects of predictor variable 
correlation: 1. VIMs are not necessary connected to discriminatory power of 
stimulus variables; 2. the size of the group of correlated variables is 
consequential (Gregorutti et al., 2013; Toloşi & Lengauer, 2011); and, 3. 
VIMs do not “directly reflect the coefficients in the generating model” 
(Nicodemus et al., 2010). Strobl et al. (2008) showed that VIMs based on the 
conditional permutation scheme described above better match the 
coefficients associated with greatest predictor discriminatory power and that 




Figure C-3. Support Vector Machine  
 Support Vector Machines (SVM) (Cortes & Vapnik, 1995) is a binary 
linear classifier which takes predictor data as input; the output is a prediction 
function. In this application, flow cytometry data are the inputs with ILD 
status (0 or 1) the prediction output. FC data are represented as points in 
space, with prediction arranged (“mapped”) into categories (0 = non-ILD; 
1= ILD) separated by as large a distance as possible (i.e., the margin as 
shown in Figure C-3). Additional FC variables follow the same mapping that 
the model is trained on, with prediction 
being which category they are assigned. 
Extensions to nonlinear partitioning are 
accomplished by expanding the predictor 
variable space through so-called kernel 
functions (Hastie et al., 2009; Kecman, 
2005). 
C.3-2 Evaluation Criteria  
Based on different purposes (either making diagnosis or predictions), 
statistical models were evaluated by various methods (Cook, N. R., 2008). In 
this thesis, I focused on predictive accuracy and goodness-of-fit given their 
appropriateness for the statistical methods evaluated. 
Source: Hastie et al., 2009 
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C.3-2-1 Predictive Accuracy 
50 Times holdout analysis was used to examine the out-of-bag (OOB) 
predictive accuracy of all the above-mentioned models. Each time of the 
holdout analysis was essentially an unequal size two-fold cross validation 
(Kohavi, 1995) with the modification that each time the training data set was 
created (by randomly subsampling approximately 90% of the original data) 
the remaining 10% was used as the test data set for validation. Because five 
models (CART, RF, CRF, SVM and mean-only model) were examined in 
total, it created 10 simultaneous hypothesis tests. In order to hold an overall 
confidence level of 95% for the combined set of hypothesis tests, each test 
could be regarded as significant if its p-value is below 5×10-3, based on 
Bonferroni correction (Dunn, 1961) for multiple hypothesis tests. 
Alternatively, Leave-One-Out Cross Validation (LOOCV) (Kohavi, 
1995) was also used to evaluate predictive accuracy of different models. It is 
a special case of cross validation in which only one observation will be held 
out at a time and the remaining data will be used as training data. This 
process will be repeated for N times (N being the number of observations). 
Eventually, all the estimated responses will be compared with the observed 
values of responses.  
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The Receiver Operating Characteristics curve (ROC) (Zweig & 
Campbell, 1993) also served as a tool for evaluating model performance. 
The Receiver Operating Characteristic curve is a graphical means of 
assessing binary classifier performance.  It is a graph of the fraction of true 
positives out of the actual positives (TPR = true positive rate, generally 
known as sensitivity – plotted on the ordinate) against the fraction of false 
positives out of the actual negatives (FPR = false positive rate which equals 
one minus specificity – plotted on the abscissa) for varying discriminant 
thresholds (Zweig and Campbell, 1993). 
C.3-2-2 Goodness of Fit 
The whole data set was used to construct the best candidate models 
without holding any observation. The model would then generate continuous 
estimation of response variable for each observation, which would become 
potential cut points for converting continuous response into binary values. 
ROC curves based on these cut points values were then plotted to indicate 
goodness of fit for the model of interest. 
After the best model was found, Variable Importance Measures (VIMs) 
would be extracted from the best model. Statistical significance of the top 
certain number of most important variables as a group will be examined 
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using an algorithm named Gene Set Enrichment Analysis (GSEA), which 
will be illustrated in the next section.  
C.4 Gene Set Enrichment Analysis 
C.4-1 GSEA Algorithm 
A gene set is a manipulatable number of genes in a typically very long 
DNA sequence (Yang et al. 2010). The key attribute here (that was 
discovered early on in genomics) is that analyses involving the study of only 
one gene at a time were of limited usefulness. What was needed was to 
examine sets of genes, with the determination of gene set size a critical 
issue. This in turn led to Gene Set Enrichment Analysis (GSEA) (Mootha et 
al. 2003; Subramanian et al., 2005). The idea of coordinated, multiple FC 
expression movement seemed applicable to this work, thus gene sets became 
FC sets. An example of the GSEA algorithm can be found in the “Methods” 
section of (Subramanian et al., 2005).  
The following will describe how the GSEA algorithm was adapted to 
this research. Three main components of the GSEA algorithm are the ranked 
list, gene set of interest and random walk. First, any suitable metric that can 
measure the correlation between a given phenotype and gene expressions 
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can constitute the ranked list (Subramanian et al., 2005). In our analysis, 
correlation coefficients between flow cytometry variables and a specific 
phenotype (e.g., ILD) are computed and ranked. The second component - 
gene set of interest (FC set in this study) - can be determined in differing 
ways including literature-based information, biological guidance from 
experts and identification via model inference. In this research, the Variable 
Importance List from the best model Conditional Random Forest (CRF) 
(Strobl et al., 2009) was used to identify FC sets. Third, after the FC set is 
identified, a random walk is performed using ranked correlation coefficients 
between response ILD and all flow cytometry variables. The process 
involves moving the FC set down the ranked list from top to bottom and 
recording the running sum for each step. If a variable in the ranked list is 













where G is size of the FC set and N is the total number of FC variables (116, 
or later 112). Below in Figure C-4 is a schematic representation of GSEA. 
 
               Figure C-4. Schematic Representation of GSEA Algorithm 
Having obtained the random walk, the maximum deviation from zero 
(absolute value), namely Enrichment Score (ES) will be recorded in order to 
evaluate the degree of enrichment.  
C.4-2 Permutation Test 
To examine the statistical significance level of ES*, a permutation test 
(Subramanian et al., 2005) for 10,000 times will be performed. Basically, the 
response values of all the subjects in the data matrix will be shuffled while 
remaining part of the data will stay the same in each permutation. After each 
shuffling, a new data set will be generated and the ranked list, i.e., sorted 



















identified previously will go through the newly calculated ranked list, a new 
random walk and corresponding ES will therefore be obtained. For 10,000 
permutations, there will be 10,000 values of ES. The p-value of this 
permutation test is the total number of ES that are at least as large as the 
observed ES*, divided by 10,000.  
If a group of variables, or a set, is statistically significant, it means 
that the corresponding ES of the random walk will be a relative large 
number, and only very few simulated ES in the permutation test will be 
higher than the observed ES, i.e., the p-value of permutation test is smaller 
than prescribed significance level such as 0.05.  
If the permutation test of the GSEA algorithm indicates that the FC set 
is statistically significant, there were two analysis directions – drawing 
statistical inference and making predictions. In the following two sections, I 
will present details regarding these analysis directions, starting with 
randomized filter design that is a novel screening techique differentiating 
SSc patients with ILD from those without based on the best FC set, followed 
by stepwise GLM, a tool used to draw statistical inference with respect to 
the association between the responses and FC variables.  
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C.5 Randomized Filter Design and Testing for ILD vs. no-ILD 
Classification 
By using the new method combining data mining and GSEA, data 
dimensionality can be reduced. Essentially, a group of FC variables would 
be identified. In this research, it was found that none of the models 
implemented has high predictive accuracy when response variable is ILD 
(see §D.2). Therefore, the first analysis direction was to create a 
generalizable method and practical tool for assessing patient’s ILD status 
given their FC data. The original motivation derived from the observation 
that assigning thresholds to individual FC expressions and applying these 
thresholds (in the form of a filter) had success in identifying SSc patient’s 
ILD status. In our filter design, a patient is declared ILD if any of their FC 
expressions is above a positive or below a negative standardized threshold in 
the FC set.   
Mathematically, the logic of a filter can be described as the follows.  
Let’s define the following parameters: 
K – number of components, or FC variables in a filter; 
I – number of patients; 
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FCki – binary variable indicates whether the ith patient’s kth FC expression is 
above an upper threshold Ui or below a lower threshold Li ;  
Zi  - binary variable indicating whether the ith patient has ILD or not. We 
have: 
FCki = �
1, 𝑖𝑖 𝐹𝐹𝑘𝑖 >  𝑈𝑖  𝑜𝑜 𝐹𝐹𝑘𝑖 <  𝐿𝑖  
0, 𝑜𝑜ℎ𝑒𝑜𝑒𝑖𝑒𝑒  
∑ 𝐹𝐹𝑘𝑖𝐾𝑘=1  ≤ M*Zi 
where, M is a large number. If Zi equals 1, then the patient has ILD and else 
otherwise.  
We experimented with different metrics to assess filter performance: 
(1) the ratio of number of predicted ILD patients to the sum of correctly 
predicted ILD and incorrectly predicted no-ILD patients; (2) the ratio of the 
number of predicted ILD patients to the true number of ILD patients (i.e., 
the True Positive Rate); (3) The product of (1) and (2) (which penalizes 
filters with good ILD prediction but poor no-ILD prediction); and (4) The 
fraction of total misclassified patients (the Overall Misclassification Rate, 
OMR) that equally weights both forms of misclassification. We decided on a 
two-level metric (OMR with TPR used break ties if necessary) because we 
had discovered that in some situations, best filters were not unique 
(Examples could be found in §D.6).  
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Standardized threshold deviates were computed using the FC 
expression ranges from the IRIS data. Thresholds were randomly generated 
using a uniform generator (R Core Team, 2013) which is an efficient way to 
explore a large unknown parameter space due to simplicity of coding. The 
design process is computationally challenging in that we have N FC 
variables with which to construct filters, but no a priori knowledge of how 
many variables and which variables should be included in any particular 
filter. A conservative but computationally expensive approach would 
involve full combinatorial expansion, that is, we would construct filters 
comprised of ( )1N , ( )2N , … , ( )NN  FC variables, which  represents a very large 
number with increasing N. Adding to the computational challenge, stochastic 
simulation is performed many times for each filter realization. Being 
completely random in nature (i.e., we have no biological or other guidance 
to suggest which variable subsets and respective thresholds are likely to 
perform well) it follows that the vast majority of filters we create will 
perform poorly in a validity test (their Overall Misclassification Rate will be 




C.6 Stepwise GLM 
Having identified a group of FC variables, the data dimension reduced 
and therefore the ‘Large P small N’ issue no longer held. Parametric method 
especially Stepwise General Linear Model analysis was used to draw 
statistical inferences and also further reduce the dimensionality of the data. 
After a full model is fitted, a stepwise algorithm in both directions (forward 
and backward) was applied to find the “best” model using the Akaike 
Information Criterion (AIC) (Akaike, 1981): 
AIC = -2LL + 2p  
where, LL is the maximum log likelihoods and p is the number of 
parameters. AIC was chosen for the reason of obtaining a model with good 
fit but as smaller number of parameters as possible. 
Starting with a full model (many parameters) a backward algorithm is 
first used - remove one variable at a time (i.e., make the model smaller) to 
determine whether AIC decreases. When AIC no longer decreases by a 
prescribed amount, we then declare the current model as best. Forward 
algorithm is the opposite. Start with a small model, say only the intercept 
term is involved, then one variable at a time is added to see how 
AIC changes.  
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The stepwise algorithm (Hastie et al., 2009; Ramsey & Schafer, 2012) 
combines forward and backward algorithms. No restrictions are made 
regarding which direction to move. Adding a variable or removing a variable 
are acceptable as long as AIC decreases by a prescribed (threshold) amount. 
C.6-1 Drop-in-Deviance test 
Consider two models: one with more parameters (Full model, denoted 
F) and the other with fewer parameters (Reduced model, denoted R). By 
defining Deviance as the following: 
D = C -2LL  
where, D means Deviance, C is constant and LL is the maximum log-
liklihood,  
Deviance_F will in general be less than Deviance_R  because a model 
with more parameters will tend to fit the data better. Deviance 
approximately follows a Chi-square distribution with degree of freedom 
equal to the difference of the number of parameters between the two models 
(Nelder & Wedderbu, 1972). The conventional goodness-of-fit Test is a 
special case of Drop-in-Deviance in which the full model is “saturated” with 
n parameters (n being the sample size). An alternative way of showing 
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goodness-of-fit of the model is to plot an in-sample ROC curve and calculate 
the Area Under Curves (AUC). These ROC curves will be in-sample 
because the stepwise GLM model will not be used for making predictions 
but drawing statistical inferences. Therefore, they are different from those 
out-of-sample ROC curves.   
We therefore have adapted and integrated three approaches, including 
CRF, GSEA and stepwise GLM, to define a group of statistically significant 
variables (therefore reducing the dimensionality of the data set). Recall that 
the output of CRF – the Variable Importance List, is used as input to GSEA, 
which in turn yields the best FC set associated with highest ES. This set of 
FC variables serve as the input covariates for the stepwise GLM of which 
the fitted coefficients are instrumental in interpreting the underlying 
biological significance of different subsets of T cells in the occurrence and 
development of SSc-ILD.  
In the next chapter, results associated with the above-mentioned 





In this chapter, the PCA results will be presented first (§D.1) which 
shows that an inability to interpret the created principal components is an 
issue. Therefore, these PCA results were not further utilized. In Section §D.2, 
performance indices, such as predictive accuracy and goodness-of-fit, of the 
four data mining models were compared. The variable importance measures 
were extracted from the best model and became input to the Gene Set 
Enrichment Analysis (GSEA) of which the results are presented in Section 
§D.3. Results regarding robustness of the GSEA algorithm are presented in 
Section §D.4.  Based on the FC sets identified in Section §D.3, on one hand, 
randomized design filters were constructed to differentiate SSc patients with 
ILD from those without. Details with respect to refining the filters in order 
to reduce misclassification rates are shown in Section §D.5, and validation 
results of the best filters found are presented in §D.6. On the other hand, 
stepwise GLM and partial dependence plots (PDP) analysis using CRF are 
used to draw statistical inference from the identified FC set, whose results 
are included in Sections §D.7 and §D.8.  
Through Sections §D.2 to §D.8, the phenotype of interest was ILD. In 
Section §D.9, the same procedures (CRF-GSEA-Stepwise GLM/PDP) were 
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applied to another phenotype ‘Cancer’. In order to examine inter-
relationship between phenotype ILD and Cancer, results of GSEA inter-
comparison of these two are presented in Section §D.10.  
Next, three different methods of determining FC sets were evaluated 
including, biological information (§D.11), Student’s t-test statistics (§D.12) 
and p-values from point-wise GLM (§D.13).  
This chapter closes in Section §D.14 with results of CRF-GSEA-
stepwise GLM analysis using other phenotypes such as Anti-topoisomerase I 
antibodies (ATA, or anti-Scl-70 antibodies) and anti-centromere antibodies 
(ACA).   
D.1 Predictor variable correlation - PCA 
Predictor variable correlation exists due in part to the hierarchical 
relations among FC variables in each panel of the data set. Without 
consideration of input variable correlation, results can be adversely affected. 
Consider for example the estimated p-value of the GSEA test (a developed 
statistical test described in section §C.4 Gene Set Enrichment Analysis). 
Variable correlation has the effect of making the p-value smaller than what it 
really is because highly correlated variables tend to cluster towards certain 
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area in a ranked list, thus producing a nonconservative result. A traditional 
method for dealing with colinearity between variables is to use Principal 
Components Analysis (PCA). Application of PCA to the IRIS data showed 
that the first 10 principal components (PC) explained 57% of the total 
variance and more than 30 components are needed to explain 90% of the 
total variance of the 112 variables. Note that these results are based on the 
FC variable correlation matrix as opposed to the original FC expressions to 
avoid scaling inconsistencies. 
 
Figure D-1. Cumulative Variance Explained for Different Number of PC 
Table D-1 Cumulative Variance Explained for Selected PC Number 
PC number 10 22 33 71 
Cumulative Variance 
Explained  57% 80% 90% 100% 































This suggests that PCA can reduce the dimension of the data set, but 
the degree of reduction did not outperform the hybrid CRF-GSEA approach 
because the number of principal components are larger than the number of 
variables in the best FC set(results are shown in §D.3). Moreover, the 
principal component variables (weighted FC expressions) are difficult to 
interpret clinically or biologically, in that one PC is a linear combination of 
more than 100 FC variables of which each is associated with different 
loadings. The loadings of each PC can be found in Appendix I.4. In that 
PCA was not useful in terms of interpretability, no further analysis 
concerning PCA were performed and other unsupervised machine learning 
methods such as factor analysis were not attempted as well.    
In the next section, I will present results regarding model performance 
of the data mining methods evaluated in this work.  
D.2 Data Mining Model Performance 
Five classification methods were tested (Classification and Regression 
Trees (CART), Random Forests (RF), Conditional Random Forests (CRF), 
Support Vector Machines (SVM) and a mean-only model) using 112 FC 
expressions as predictor variables and ILD as response. The mean-only 
model simply uses the mean value of the response in the training data as 
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future prediction. Mean Absolute Errors (MAEs) and Mean Squared Errors 
(MSEs) are the two measurements of the comparison. They were calculated 














= −∑                               
where, n = 50, yı�  is the estimate of i
th response variable, and yi is the actual 
value of the ith response variable. Table D-2 shows the mean MAE and mean 
MSE of the five approaches. 
Table D-2 Mean MAE & Mean MSE of 50 Times Holdout Analysis for Data Mining 
Approaches 
 mean MAE mean MSE 
CART 0.471 0.356 
RF 0.482 0.246 
CRF 0.492 0.248 
SVM 0.502 0.253 
mean 0.502 0.254 
 
When comparing predictive accuracy between two models, a one-
sided two samples Student’s t-tests was performed to examine whether the 
mean of the two corresponding vectors of MAEs or MSEs are equivalent.  
RF and CRF perform best (by a small amount) but their differences in MAE 
and especially MSE are not statistically significant (p-value = 0.0996 for 
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MAE and p-value = 0.785 for MSE). The mean-only result confirmed our 
understanding that this statistical estimation problem is very flat (i.e., no 
single FC variable or small subset of variables is highly associated with ILD 
status). From their Receiver Operating Characteristic (ROC) curves 
performance (Figure D-2a) RF, SVM and CRF emerged as the most 
effective classifiers. All consistently yielded AUC (Area Under Curve) 
values of greater than 0.95. Thus, RF, SVM and CRF fit the data well and 
exhibited high true positive rates (out of the positives) and few false 
positives (out of the true negatives) , but this is training performance. As 
shown in Figure D-2b, all four models were fairly poor out-of-sample (i.e., 
out-of-bag, OOB) classifiers based on the Leave-One-Out Cross Validation 
(LOOCV). The OOB AUCs for all models evaluated are between 0.5 and 
0.6. The highest AUC is associated with RF (0.57) while the lowest 
associated with SVM (0.53). This is the reason why we created screening 







Figure D-2a. Goodness-of-Fit ROC Curves for Various Data Mining Methods 
(Phenotype is ILD) 
 
Figure D-2b. Leave-One-Out Cross Validation (LOOCV) ROC Curves for Various 












































Conditional Random Forest (CRF) was eventually chosen over RF 
and SVM for several reasons. First, the permutation computing scheme for 
variable importance measures (VIMs) in CRF provides a “more fair means 
of comparison that can help identify the truly relevant predictor variables” 
(Strobl, 2008; Strobl, Hothorn, & Zeileis, 2009). Specifically, it enforces the 
requirement that each predictor variable that is selected as a split variable in 
each tree must be strongly associated with response variables (through 
hypotheses testing under an unbiased conditional inference framework) 
(Hothorn, Hornik, & Zeileis, 2006).  This is a robust way of enhancing the 
discriminant power of a predictor variable and is particularly useful for our 
IRIS data set in which a significant number of FC expressions are highly 
correlated. In contrast, the VIMs of RF were unstable and suffered from 
“correlation bias” due to effects related to predictor correlation, including: 
(1) VIMs were not necessarily aligned with the discriminant power of the 
stimulus variable; (2) the size of the group of correlated variables has a 
pronounced effect (Gregorutti, B Michel, & Saint-Pierre, 2013; Toloşi & 
Lengauer, 2011); and, (3) VIMs did not “directly reflect the coefficients in 
the generating model” (Nicodemus, Malley, C Strobl, & Ziegler, 2010). 
Using the conditional importance measure, Strobl et al. (2008) showed that 
VIMs based on the conditional permutation scheme better reflect the pattern 
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of the coefficients associated with predictor discriminant power and the 
variability was “lower than that of the unconditional importance within each 
level of mtry” (mtry is the parameter in R specifying the number of 
covariates randomly selected to split the node in each tree of the RF model). 
In this research, it was discovered that the conditional permutation scheme 
exerted almost no influence on the VIM output. Also, the computational 
burden of executing the conditional permutation scheme was particularly 
expensive in that the computing time increased exponentially as the number 
of observations increased. Eventually, VIM information was extracted from 
CRF without conditional permutation scheme. Second, the ROC curves of 
the fitted CRF, RF and SVM models suggested that RF and SVM might be 
overfitting. CRF misclassified 5 patients out of 79 whereas RF and SVM 
had 100% predictive accuracy. Third, the ES based on the variable 
importance list drawn from CRF were always larger than those of RF 
regardless of configuration settings, including the number of trees and mtry. 
The results are shown in Table D-3.  
Table D-3 Enrichment Scores of RF vs. CRF 
mtry ntree RF CRF 
5 1000 21.77 23.43 
11 1000 20.76 22.34 
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To the best of the author’s knowledge, no existing predictive methods 
could yield well predictive accuracy when the response variable is ILD. 
However, as to the randomized filter design, promising results were obtained 
in terms of predictive accuracy of this screening tool whose validation 
results will be presented later in Section § D.6.  
Recall that the Gene Set Enrichment Analysis (GSEA) was designed 
and adapted in this study to capture combined effects of a group of FC 
variables. In the following sections, performance of GSEA (in §D.3) and 
robustness of this algorithm (in §D.4) will be demonstrated.  
D.3 GSEA Performance 
At this point in the analyses the IRIS data set changed and consisted 
of the original set of patients in IRIS071813, modified by: (1) removing the 
four dropped FC variables; (2) updating against IRIS030814; (3) adding 
missing fvcstpp/ILD data. From 112 FC variables, we found via the CRF-
GSEA algorithm 27 FC variables to be the most important in differentiating 






Table D-4 Most Important Variables Identify via CRF-GSEA algorithm  





































pol8ccr5 pol8ccr5cxcr3neg memem4 pol8ccr5cxcr3 act4103 
act425lo memem478 act8103 memem8 mememra87 
act425103 traff4cxcr6 memnaive4 act425tot memcm878 
act410371 pol4ccr6 memem878 mememra478 memcm4 
memcm478 traff8cxcr4 mememra4 act425hladr memcm8 
act4103hladr memem48    
Below is the random walk for FC27. Figure D-3 shows that there is a 
peak between the 1st ranked FC variable and the 40th FC variable, and a 
valley when the ranking of FC variable was around 90. The former, in 
genomics research, is called up-regulated and the latter down-regulated. It 




Figure D-3. Random Walk that Results from FC Set Comprised by Top 27 Most 
Important Variables  
Figure D-3 shows that the highest ES is associated with FC set size 
27. Figure D-4 is the full set of GSEA results that identified the best 
performing set as FC27. The corresponding ES statistical significance levels 
are presented in Figure D-5. The estimated p-values were calculated based 
on permutation test described in §C4-2. It can be seen in Figure D-5 that the 
estimated p-values of the FC set were smaller than 0.01 when the FC set size 
is between 15 and 40. 
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Figure D-4. Enrichment Scores of GSEA for Different FC Set Sizes  
(Phenotype is ILD) 
 
Figure D-5. P-values associated with Enrichment Scores for Different FC Set Sizes 
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The results in this section indicate that the GSEA algorithm can 
identify the best set size of a group of FC variables based on the Enrichment 
Scores (ES). When the response variable was ILD, the best FC set size was 
27 because its associated ES was the largest. This FC set of 27 variables is 
also considered as statistically significant based on the permutation test. In 
Section §D.4, I will present results with respect to robustness of the GSEA 
algorithm.  
D.4 Robustness of the GSEA algorithm 
D.4-1 Random Walk with differing FC set sizes 
All FC sets created to date (including the best performing – FC27) 
were based on the top-ranked variables in the CRF variable importance (VI) 
list. To examine the validity and robustness of this procedure, random walks 
were plotted using different FC set selection criteria.  Shown in Figure D-6 
is the random walk that results from an FC set comprised of the top 5 FC 




Figure D-6. Random Walk with Top 5 Most Important Variables  
In Figure D-6, it shows that the random walk was enriched in both 
ends (displayed as a peak and a valley) but have a relatively low ES if the 
FC set contains the top 5 most important variables. In addition, the 
maximum deviation from zero, or the supremum, is positive value, which 
means that this random walk is up-regulated. Note that enrichment score is 
the absolute value of the maximum deviation from zero and therefore it is 
always positive. When the FC set size was increased to 10, similar 
enrichment structure of the random walk showed up and ES increases 
substantially (see Figure D-7). 







                 












Figure D-7. Random Walk with Top 10 Most Important Variables 
Keep increasing FC set size in this situation will yields similar 
enrichment structure of a random. Figure D-8 shows the random walk with 
FC set size 50 and the random walk is up-regulated as well. The Enrichment 
Score did not increase substantially in that adding more FC variables to the 
FC set does not necessarily contribute the increase of the maximum 
deviation from zero.  








                 












Figure D-8. Random Walk with Top 50 Most Important Variables 
So far, the FC set is all determined by choosing the FC variables from 
the top of the variable importance measure (VIM) list. Next, the GSEA 
performance was examined when the FC set was determined by choosing 
certain sequence of the variable importance list as opposed to choosing 
variables from the top. For example, a FC set can be determined by choosing 
from the 20th to the 30th variables in the VIM list. Shown in Figure D-9 is the 
random walk that resulted from an FC set comprised of the 20th to 30th 
variables in the VIM list. It can be seen that the enrichment structure switch 
to down-regulation. In other words, the associated maximum deviation 
becomes negative and its absolute value, or the ES, decreased.  
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Figure D-9. Random Walk with Top 20th to 30th Most Important Variables 
 
Figure D-10. Random Walk with Bottom 10 Most Important Variables 





                   
   




               
   
















Response is ILD – Enrichment Score = 10.5 
Response is ILD – Enrichment Score = 7.99 
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Figure D-10 shows the random walk using an FC set comprised of the 
bottom 10 variables of the VI list which are considered by Conditional 
Random Forest the least important variables. Almost no enrichment structure 
can be found in this setting, and the ES is less than 8.  
In sum, the GSEA algorithm is robust when the size of the FC set 
differs. In specific, the random walk is always up-regulated with large 
enrichment score if the FC set is determined by choosing FC variables from 
the top of the variable importance list. In the next sub-section, I will examine 
robustness of the GSEA permutation test.  
D.4-2 Robustness of the GSEA Permutation Test 
Results in this section were based on data set IRIS071813. When the 
number of permutations varied ranging from 1000 to 10,000,000, the 
estimated p-value of the GSEA test changed only slightly (between 0.019 
and 0.0262) - all significant at level 0.05. This implies that the GSEA 
significance level is robust to permutation number. Considering both 
reliability and computational efficiency, 10,000 was chosen as the 
permutation number for GSEA.  
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For the next several sections (from §D.5 to §D.8), I will present 
results regarding the two directions analysis mentioned in §C.1.  
D.5 Refinements in Filter Design  
In this section, I describe two methods of refining the filters design 
procedure - – threshold tightening and pre-partitioned FC classification, so 
as to reduce overall misclassification rate (OMR). The corresponding 
improvements of the filters performance associated with each method in 
terms of OMR will also be presented. Because of the superior improvements 
by using the second method, details of the associated best filters regarding 
filter components and associated thresholds are also explored and shown 
later in this section. Results in this section were based on data set 
IRIS071813. 
The first method refers to a procedure in which the ranges of random 
thresholds for each variable in the FC set were narrowed through an 
examination of well performing filters. Consider the case of 10,000 random 
filter trials, from which there emerged 200 filters for which the smallest 
Overall Misclassification Rate, or OMR, was about 0.24. It means that if 
there are 100 patients then we have 24 patients misclassified by the random 
filter. The random threshold ranges for each FC expression was updated for 
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subsequent analyses using the FC thresholds that produced these 200 filters. 
Threshold tightening alone improved filter performance OMR to about 0.16. 
Improved OMR results with threshold refinement are due to our 
randomization procedure wasting less time evaluating bad-performing filters.  
The second approach, Pre-partitioning using CART (with pruning at 
the 2nd level split producing three groups), was used to classify the data set 
into N subgroups with N being the number of end branches (Figure D-12). 
Random filter design was then applied to each subgroup. This method 
substantially improved filter performance. At the time, the lowest global 
OMR found considering all groups was 0.09 (see Table D-5). 
Table D-5 Classification Statistics of Three Prepartioned Groups 





















31 12 19 0.03 1 0 










































≥ ≥ ≥ 
≥ 
≥ 




In one of the more recent experiments using all CART-partitioned 
groups (10) the filter-based approach successfully classified 124 of 125 SSc 
patients (OMR = 0.008). This extremely low OMR, however, needs a strong 
caveat: it may be a result of overfitting (Cawley & Talbot, 2010; Forsyth et 
al., 1994) that is, decreases in training data set error are accompanied by 
increases in validation data set error as the extent of pre-partitioning 
increases. Shown below in Figure D-11 are four pruning levels (the blue 

















Figure D-11. Four Pruning Levels of CART Pre-partitioning  
68 
 
The randomly generated threshold bounds for each FC variable were 
derived from the training set data. We then addressed the issue of which 
subsets of variables (from the set of 27 “best” variables identified through 
GSEA) should be used to construct filters. Experiments were conducted to 
see whether full combinatorial expansion was necessary, that is, did we need 
to evaluate filters with ( )271  through ( )2727  components (134,217,727 possible 
combinations of variables; recall also that for each combination, many 
random threshold realizations are generated).  Our testing showed that the 
best performing filters (those with the lowest OMR)  were consistently 
comprised of at least three and no more than six FC variables, therefore all 
subsequent analyses involved filters comprised of ( )273  through ( )276  (i.e., 
2,925 + 17,550 + 80,730 + 296,010 = 397,215) combinations of FC 
variables.  
The best performing filter at this stage of the analyses had an overall 
misclassification rate of 18.98% (15 patients misclassified out of 79). We 
next performed pre-partitioning using CART to classify the data set into 
subgroups (Figure D-11). Random filter design was then performed for each 
subgroup (there are 14 shown in total in Figure D-11, but six are child nodes 
whose parents have OMR = 0; these six node ID’s are shown in black). This 
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method substantially improved filter performance. The pre-partitioned OMR 
results are shown in Table D-6 (MC = Misclassified). 
Table D-6 OMR Results for All Pre-partitioned Levels 
CART Node # ILD # NoILD # MC # ILD MC # NoILD MC OMR 
Level 0 38 41 15 11 4 0.1878 
1-1 24 38 11 9 2 0.1774 
1-2 14 3 0 0 0 0.0 
Level 1 38 41 11 9 2 0.1392 
2-1 17 37 9 8 1 0.1667 
2-2 7 1 0 0 0 0.0 
Level 2 38 41 9 8 1 0.1139 
3-1 1 18 1 0 1 0.0526 
3-2 16 19 5 2 3 0.1429 
Level 3 38 41 6 2 4 0.0759 
4-2 3 13 1 0 1 0.0625 
4-3 13 6 0 0 0 0.0 
Level 4 38 41 1 1 1 0.0127 
Parent Node > Child Node; 1-2 > 2-3 > 3-4 > 4-5;  2-2 > 3-3 > 4-4;  3-1 > 4-1 
 
Pre-partitioning had a large effect on OMR performance, reinforcing 
our expectation that CART is a highly effective classifier and that sub-
groups of patients identified through CART are, in a sense, relatively easier 
to correctly classify. But we are mindful not to overstate this result, for the 
sub-groups with the highest OMR values also had the most patients. To 
continue this line of thought, consider an extreme situation: 79 one-patient 
“groups” with a best filter created for each. The resulting training filter’s 
OMR performance will be perfect but operationally useless, both in 
validation and clinically.  Excepting the fourth level (where only one patient 
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of 79 was misclassified) there was considerable more misclassification of 
ILD than no-ILD patients. Moreover, the result that only one patient was 
misclassified at the fourth level of pre-partitioning is strongly suggestive of 
overfitting (which is addressed below in §D-6 Validation). 
Following in Table D-7 are details of the best training filters for no 
pre-partitioning (Level 0) and all lower levels. The FC variable names are 
shown as are the corresponding standardized random threshold deviates.   
Table D-7 Details of FC Variables in Different Prepartioned Levels 
Variable/Node  0 1-1 1-2 2-1 2-2 3-1 3-2 4-2 4-3 
act4103 0.57    -1.58     
act425lo  2.10 -1.60  -1.63  1.82   
act425tot 2.29  0.07  -0.24   2.47  
act8103         1.17 
act810371 1.43 2.44 0.68 2.13   1.28  2.09 
memem4 1.05 0.98   -0.59     
memem478     -0.41 1.85   -1.07 
memem48   -0.27   2.34 1.31 1.81 0.70 
memcm478         -0.26 
memcm4k      3.12    
memem8    -1.26      
memem878 -1.23 -0.92        
mememra4        1.88  
mememra4k      2.82    
mememra478        3.46  
pol8th17   1.84    -0.68 1.26  
pol8th1th2ratio    1.64  1.67    
pol4ccr6  -1.33  -1.36      
traff4ccr3 1.88   2.31   0.61   
 
Of the full set of 27 “best FC set” variables, 19 appeared in the 
highest performing training filters. Activation and polarization variables 
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have the highest representation. Only three variables, act425tot, act810371 
and memem4 appeared in all Levels (0-4). Pre-partitioning had very 
pronounced effects on active variables within and across levels. In Level 2 
for example, node 2-2 FC thresholds are all negative (cutoff thresholds for 
those variables less than their means). For all levels, active variable sets for 
all nodes are typically very different.   
D.6 Validation of Randomized Filter Design 
Having achieved in-sample success in filter design and calibration, the 
next critical step is validation. FC profiles of SSc patients whose FC 
expressions were not involved in filter design (i.e., out of sample analysis) 
will be processed using our best performing filters. In this section, results 
two protocols (A and B) of validation test will be presented. The main 
difference of these two validation protocols lies in the way the training data 
was generated of which the details will be described below. 
D.6-1 Validation Test A  
D.6-1-1 Test A Protocol 
The training data set consists of the original set of patients in 
IRIS071813, modified by: (1) removing the four dropped FC variables (2) 
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updating against IRIS030814. The resulting set contains data on 129 patients 
(61 ILD; 68 NO_ILD) and 20 “new” validation patients were provided (6 
ILD; 14 NO_ILD), namely IRIS041314. There are fewer patients to work 
with as FC set size increases due to missing data. 
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Through pre-partitioning, it is possible to reduce training set error 
(Overall Misclassification Rate) but likely at the expense of increasing 
validation set error (i.e., overfitting) visualized as:  
 
Figure D-13. Tradeoff between OMR and CART Pre-partitioning Level 
D.6-1-2 Validation Test A Results  
With no CART pre-partitioning (Level 0) the screening tool correctly 
classified the ILD status of 80% of the validation patients. In specific, 4 out 
of 6 ILD and 12 out of 14 NO ILD were correctly predicted. Level 1 results 
are the same as Level 0. At CART pre-partitioning Level 2 the screening tool 
correctly classified the ILD status of 90% of the validation patients. Details 
of the results are shown in Table D-8. The combined Level 2 OMR is 0.1. 
Table D-8 Classification Statistics for Level 2 (Protocol A) 
FC level FC21_2-1 FC21_2-2 FC21_2-3 
actual ILD 3 3 0 
correctly predicted ILD 2 3 0 
actual  NO ILD 10 3 1 
correctly predicted NO_ILD 10 2 1 











D.6-2 Validation Test B  
D.6-2-1 Test B Protocol 
A different protocol was developed to expose our methodology to a 
potentially more demanding validation test. It involves the following 
procedures: (1) Combining original and “new” patients into one data set and 
thoroughly shuffling them; (2) Randomly selecting a training set and a 
validation set of given proportions (66.7%-33.3%). These proportions derive 
from published guidance and testing of our data following Dobbin & Simon 
(2011); (3) 120 random selections were performed involving 38,750,400,000 
screening tool design and testing stochastic simulations.  
 There are 79 patients (38 ILD and 41 NO ILD) in the training data set 
and 40 patients (18 ILD and 22 NO ILD) in the validation data set. 
D.6-2-2 Validation Test B Results  
The best training filters were validated using FC data from 40 patients 
not used in training. Without pre-partitioning, the overall correct ILD 
classification rate was 82.5 % (7 patients misclassified out of 40). Pre-
partitioning the validation patients (using the CART-derived variables and 
splitting levels developed for the training data) increases correct validation 
















of 40). This indicates that overfitting was occurring for the deepest pre-
partitioning level (the training and validation curves cross) as figure D-14 
shows. Notable is the similar OMR performance between training and 








Table D-9 gives the details of the best validation filters. Note that the 
best training filters are not the best validation filters.  
Table D-9 Details of Flow Cytometry Variables in the Best Validation Filters in 
Different CART Pre-partitioning Levels  
Variable/Node  0 1-1 1-2 2-1 2-2 3-1 3-2 4-2 4-3 
act4103   -0.08  -1.21     
act425lo 1.26  1.30   0.65  1.85  
act425tot   1.04  -1.45 0.48  1.89 1.62 
act8103 3.23    0.06     
act810371  2.69  2.43   1.05   
memem4 3.59 1.54        
Figure D-14. Training & Validation OMR at different Prepartioning Level 
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memem478         0.65 
memem48 3.94      1.83   
memcm478      -1.33 1.05   
memem8  -0.87 0.23 -0.87      
memem878        -0.97 2.05 
mememra4     1.14  5.22 1.00  
mememra478    4.78      
mememra4k  6.50        
pol8ccr4          
pol8th2      1.95 -0.68   
pol8th17   2.84      2.48 
pol8x3r4ratio  2.60  1.68  -1.28    
pol8th1th2ratio    1.10      
traff4ccr3     0.29   0.91 -0.11 
Note that each column contains information of the best filter in that particular level. 
Only 20 of the 27 “best FC set” variables were used in the best 
performing validation filters. All act4103 variables that were active in 
establishing ILD status had thresholds below their mean. On occasion we 
see thresholds that correspond to extremely high FC expressions (e.g., 5.22 
standard deviations above the mean for mememra4; 6.50 for mememra4k). 
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D.7 Generalized Linear Regression Model Results  
Results in this section were based on data set IRIS041314 (defined in 
§B-2). The estimated coefficients of the best GLM found based on the 
stepwise model selection algorithm is shown in Table D-10. The p-value of 
Goodness-of-Fit–Test (Pr( 213χ > 128.58)) is approximately 0.15, which is 
larger than 0.05. It indicates that there is no evidence that the model is 
inadequate. 
Table D-10 Estimated Coefficients of Stepwise GLM 
 
Mean Standard Error z value Pr(>|z|) 
(Intercept) -0.95 1.32 -0.72 4.70E-01 
pol8ccr5cxcr3neg -0.12 0.04 -2.81 4.89E-03 
pol8ccr5cxcr3 0.03 0.02 2.00 4.50E-02 
memem8 -0.25 0.10 -2.42 1.54E-02 
mememra87 0.43 0.18 2.43 1.53E-02 
memcm878 0.29 0.12 2.53 1.16E-02 
memcm4 -0.03 0.02 -2.00 4.54E-02 
type 1.05 0.47 2.22 2.64E-02 
scl70_ab 0.94 0.46 2.03 4.25E-02 
dd1symptom_y 0.07 0.03 2.28 2.25E-02 
     Residual deviance: 128.58  on 113  degrees of freedom 
Note: Bold values are statistically significant at 5% significance level or lower 
A Drop-in-Deviance Test comparing the Null model (or Intercept only 
model) with current model was performed with Drop-in-Deviance equal to 
39.58 (=168.16 - 128.58) and d.f. equal to 9 (=122-113). The corresponding 
p-value is smaller than 10-6, which suggests that the null hypothesis that 
coefficients of all variables in the model are equal zero is rejected. In other 
78 
 
words, the variables in stepwise GLM (pol8ccr5cxcr3neg, pol8ccr5cxcr3, 
memem8, mememra87, memcm878, memcm4, type, scl70_ab, 
dd1symptom_y) are all statistically significant.  
Table D-11 95% Confidence Interval of the Estimated Coefficients of Stepwise 
GLM 
 
Estimate 2.50% 97.50% 
pol8ccr5cxcr3neg -0.124  -0.217  -0.043  
pol8ccr5cxcr3 0.033  0.002  0.066  
memem8 -0.252  -0.472  -0.061  
mememra87 0.434  0.105  0.814  
memcm878 0.294  0.081  0.542  
memcm4 -0.034  -0.068  -0.002  
type 1.050  0.142  2.009  
scl70_ab 0.937  0.041  1.863  
dd1symptom_y 0.074  0.013  0.141  
Depending on the sign of coefficient for each FC variable, certain 
variables are negatively associated with the odds (not probability) of having 
ILD. As an example, holding the other variables constant, the odds of having 
ILD will change by a multiplicative factor of 0.8836 (or, exp (-0.12374)) 
with one unit increase of pol8ccr5cxcr3neg. In other words, the odds of 
having ILD will be 11.67% smaller with one unit increase of 
pol8ccr5cxcr3neg.  
To further explore the relative importance of the group of clinical 
variables v.s. the 6 FC variables, two reduced GLMs (clinical-only model 
and FC-only model) were fitted and compared with the stepwise GLM.   
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Table D-12 Estimated Coefficients of Reduced GLMs 
Clinical-only Model 
    
 
    Mean Std. Error z value Pr(>|z|) 
(Intercept) -1.90  0.46  -4.12  3.82E-05 
type 1.27  0.43  2.96  3.12E-03 
scl70_ab 0.93  0.41  2.25  2.46E-02 
dd1symptom_y 0.08  0.03  2.69  7.22E-03 
     Residual deviance: 147.79  on 119  degrees of freedom 
FC-only Model 
    
 
Mean Std. Error z value Pr(>|z|) 
(Intercept) 1.07  1.10  0.97  3.32E-01 
pol8ccr5cxcr3neg -0.11  0.04  -2.73  6.30E-03 
pol8ccr5cxcr3 0.03  0.02  2.06  3.94E-02 
memem8 -0.27  0.09  -2.88  3.99E-03 
mememra87 0.47  0.17  2.82  4.79E-03 
memcm878 0.32  0.11  2.99  2.77E-03 
memcm4 -0.05  0.02  -2.94  3.32E-03 
     Residual deviance: 141.56  on 116  degrees of freedom 
 
Table D-13 Drop-in-Deviance-Test Comparing Stepwise GLM and Reduced GLMs 
 
Drop-in-Deviance  Drop-in-d.f. p-value 
Clinical-only Model 19.21 6 3.83E-03 
FC-only Model 12.98 3 4.68E-03 
In Table D-13, both of the estimated p-values of the Drop-in-
Deviance-Test are smaller than 0.005, which implies that there is strong 
statistical evidence that the 3 clinical variables and the six FC variables 
individually and as groups are highly associated with the odds of having 
ILD. In particular, with six FC variables, the residual deviance of stepwise 




D.7-1 Case-Influence Statistics  
During the process of searching for a statistical model that fits the data 
set well, it is important to examine the individual influence of selected data. 
Case-influence statistics are mathematical measurements used to 
characterize such individual influence (Ramsey & Schafer, 2012). Many of 
them have been used to further improve fitted models (Belsley, Kuh and 
Welsch (1980), Cook and Weisberg (1982), Williams (1987), Fox (1997, 
2002)). Four different kinds of statistics have been utilized in this research: 
leverages, standardized residuals and Studentized residuals, Cook’s 
distances.  
(1) Leverage measures the distance between the explanatory variable value 
of a case (in this research, a case means a patient) and the mean of the 











      
where, ix is the explanatory variable value of the ith case, x is the average of 
all x, and n is the sample size. 
(2) Standardized residual is the residual of a case divided by the variance. Its 














where, îε is the deviation or residual of the ith case, σ̂ is the estimated 
standard deviation from the fit, and ih is the leverage of the ith case. 
(3) Studentized residual is similar to standardized residual except using a 
different definition of variance in which the calculation does not include the 













(4) Cook’s Distance measures the effect of omitting the ith case upon the 













=∑   
where, ˆjY is the j
th fitted value based on a fit model using the entire data set, 
( )
ˆ
j iY  is the j
th fitted value in a fit excluding the ith case from the data set, p is 
the number of parameters and σ̂ is the estimated standard deviation from the 
fit. As shown in Figures D-15, few patients had Cook’s distances and 
leverage that were distinct from the majority. The Studentized residuals and 
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standardized residuals plots also suggest that no outliers were found based 
on stepwise GLM.  


























































































D.8 Partial Dependence Analyses 
Results in this section were based on data set IRIS041314. A Partial 
Dependence Plot is a tool to estimate the marginal effects of a subset of 
explanatory variables (usually less than 3) upon a response, accounting for 
the effects of all other FC variables on that response (Hastie et al., 2009). 
The method used is CRF. The PDP procedure is:  
- Select a FC variable in the FC set 
- Sort the expressions of that variable in the IRIS data set 
- Replace all expressions of that variable with the first expression in the 
sorted list; No other FC expressions in the data set are changed 
- Perform CRF with that newly created IRIS matrix (only one column 
has changed and all of that column’s row entries are the same); the 
CRF result is probability of having ILD 
- Repeat for all the other expressions in the sorted list; plot completed 









Figure D-16. Partial Dependence Plots for FC Variables (Phenotype is ILD) 
 
Figure D-16 shows that as the values of FC variables memcm878 and 
memcm4 increase, the probability of having ILD becomes larger. The 
remaining four FC variables had the opposite effect on the probability of 
having ILD.  Increasing trends for the two memory panel variables were 
limited between probability 0.395 and 0.41, while the ranges of declining 
trends were relatively larger. FC variable memem8 has the smallest decrease 
(from about 0.415 to 0.395). Mememra87 and two polarization variables 


























Standardized FC Expression 









D.9 Phenotype as Cancer 
So far, the phenotype of interest has been ILD. In this section, the 
same procedures (CRF-GSEA-Stepwise GLM/PDP) were applied to another 
phenotype ‘Cancer’ in order to identify a group of flow cytometry variables 
as a whole that are strongly associated with cancer in SSc patients.  
D.9-1 CRF-GSEA 
Using the IRIS071813 data set (Section §B-2), CRF classification was 
first performed. Through Gene Set Enrichment Analysis, the relationship 
between FC set size and Enrichment Score was examined. Next, the FC 
variables that comprise the FC sets were identified.  
Following are some preliminary results, beginning with an in-sample 
CRF ROC curve and continuing through FC set size experiments, associated 
p-values, the GSEA Random Walk and finally a table of FC expressions in 
FC set sizes 5 to 50. In Figure D-17, it shows that the AUC of the in-sample 
ROC curve associated with CRF was 1, which suggests that the CRF model 





Figure D-17. ROC Curve for CRF (Phenotype is Cancer) 
 
Figure D-18. Enrichment Scores of GSEA for Different FC Set Sizes (Phenotype is 
Cancer) 





        
  
 


















Figure D-18 shows that the highest ES is associated with FC set size 
12. ES increases as FC set size becomes larger from set size 5 to set size 12 
until it reaches the peak 34.6, but displays a sharp declining trend with 
greater FC set size. The estimated p-values associated with each ES are all 
below 10-4 when FC set size is smaller than 30 (see Figure D-19) but 
become less significant afterward. However, they are all below the 
significance level 0.05.  
 
Figure D-19. P-values associated with Enrichment Scores of GSEA for Different FC 
Set Sizes (Phenotype is Cancer) 
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Figure D-20. Random Walk that Results from FC Set Comprised by Top 12 Most 
Important Variables 
D.9-2 Stepwise GLM 
All the results shown from now to the end of this section were based 
on data set IRIS041314. A logistic binomial linear regression model with 12 
FC as covariates was fit to estimate the binary outcome CANCER, followed 
by the stepwise variable selection algorithm. The results are shown in Table 
D-14.   
 









                 
   












Table D-14 Estimated Coefficients of Stepwise GLM (Phenotype is Cancer) 
 
Mean Standard Error z value Pr(>|z|) 
(Intercept) -4.63 1.21 -3.82 1.33E-04 
act4103hladr 3.05 1.09 2.80 5.07E-03 
traff4ccr3 0.66 0.33 2.02 4.39E-02 
act825 0.10 0.04 2.49 1.28E-02 
pol4th2 -0.19 0.08 -2.27 2.35E-02 
     Residual deviance: 66.302  on 134  degrees of freedom 
 From the goodness-of-fit Test (p=0.9999998; a large p value indicates 
that the model is adequate) and Drop-in-Deviance test comparing the current 
model with the Null model (p <10-5), we know that stepwise GLM is 
sufficient to estimate response CANCER.  
Table D-15 95% Confidence Interval of the Estimated Coefficients of Stepwise 
GLM 
 
Estimate 2.50% 97.50% 
act4103hladr 3.053 0.983 5.384 
traff4ccr3 0.658 0.043 1.350 
act825 0.103 0.024 0.189 
pol4th2 -0.189 -0.377 -0.046 
Table D-16 95% C.I. of the Exponentiated Estimated Coefficients (of Stepwise GLM) 
Subtracted 100% 
 
Estimate 2.50% 97.50% 
act4103hladr 20.182 1.672 216.823 
traff4ccr3 0.930 0.044 2.859 
act825 0.108 0.024 0.208 
pol4th2 -0.173 -0.314 -0.045 
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Four FC variables were 
discovered to be highly associated 
with phenotype ‘Cancer’. 
Stepwise GLM and Partial 
Dependence Plot were useful in 
drawing statistical inference from 
the identified FC set. 
Among the 4 FC variables, pol4th2 was negatively associated with the 
odds of having cancer, i.e., holding the other variables constant, the odds of 
having cancer will be 17.3% smaller with one unit increase of pol4th2. The 
other three variables are positively 
associated with the odds of having cancer, 
among which variable act4103hladr had 
the strongest association – approximately 
20 times higher with one unit increase in 
the FC expression.  
Note:  
act4103hladr = CD3+/CD4+/CD8-/CD103+/HLADR+ 
traff4ccr3 = CD3+/CD4+/CD8-/CCR3+ 
act825 = CD3+/CD4-/CD8+/CD25+ 
pol4th2 = CD3+/CD4+/CD8-/CXCR3-/CCR4+/CCR6- 
 
The ROC curve for this model was also plotted (see Figure D-21). The 
Area Under Curve (AUC) is 0.8688, which supports the conclusion that 





Figure D-21. In-sample ROC Curve for Stepwise GLM 
Stepwise GLM yielded the result that only 4 FC variables remain. 
Each is statistically significant at the 5% level. To further explore 
relationships among these covariates, a matrix of scatter plots between pairs 
of these variables is presented in Figure D-22. Two different symbols are 
used to represent patients with (red triangle) and without (black square) 
cancer diagnosis. We find in Figure D-22 that variable pol4th2 is particularly 
intriguing in this context. In the last column of the matrix of scatter plots, the 
red triangles cluster cohesively toward the left while the black dots spread 
more toward the bottom.  
 
 























Figure D-22. Matrix of Scatter Plots for 4 FC Variables in GLM 
D.9-3 Diagnostic Statistics  
Based on four case influence statistics described in Section §D. 7-1, 
two patients (ID:2202, 3083) are considered as isolated observations 
(identified by the blue arrows in the figures). Note that when the response 
variable was ILD, no isolated observations were found. To determine their 
influence, a stepwise GLM was implemented using the data set without 





































































Table D-17 Estimated Coefficients of Stepwise GLM 
 
Mean Standard Error z value Pr(>|z|) 
(Intercept) -4.81 1.43 -3.37 7.63E-04 
act4103hladr 5.52 1.63 3.39 6.89E-04 
traff4ccr3 0.67 0.38 1.78 7.50E-02 
act825 0.11 0.05 2.10 3.53E-02 
pol4th2 -0.35 0.13 -2.70 7.04E-03 
     Residual deviance: 50.893on 132  degrees of freedom 
 Compared with output of the stepwise GLM with full data set, the 
coefficients of variable act4103hladr (from 3.05 to 5.52) changed 
enormously while the others less so. Variable traff4ccr3 became less 















































































significant but the p-values associated with act4103hladr and pol4th2 
decreased. The p-value of the corresponding Drop-in-Deviance test is 8.54e-
06, which highly suggests that these 4 FC variables are statistically 
significant. The goodness-of-fit Test (§C.5-1) gives a p-value that is almost 
1. It indicates that there is no evidence for the inadequacy of the fitted 
model. For these four FC variables, Student’s t-tests were undertaken with 
the null hypothesis that the mean difference between FC variable 
expressions is zero for SSc cancer and SSc non-cancer patients. Shown in 
Table D-18, zero was not included in the 95% C.I. of the mean difference 
between non-cancer patients and cancer patients when the FCs of interest 
were act4103hladr and traff4ccr3. It suggests that the act4103hladr and 
traff4ccr3 expression differs between cancer patients and non-cancer 
patients with a 95% confidence interval.  
Table D-18 95% C.I. for 4 FC Variables in GLM based on Student t-tests 
FC Variable mean difference 95% C.I. 
act4103hladr -0.290357 -0.31972 -0.26099 
traff4ccr3 -0.8182419 -1.31324 -0.32324 
act825 -5.3151505 -40.6785 30.04821 
pol4th2 3.8572312 -31.115 38.82946 
 Next, stepwise GLM without CRF-GSEA using the full data set was 
fitted to evaluate the influence of the CRF-GSEA procedure. The results (see 
Table D-19) show that 16 FC variables out of 112 remain but none of them 
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are statistically significant. The implication here is that our hybrid CRF-
GSEA procedure is highly effective in selecting important FC sets. 
Table D-19 Details of the Fitted GLM Using Full Data set 
  Estimate Std. Error z value Pr(>|z|) 
(Intercept) -2821.09 226601.20 -0.01 0.99 
mememra48 2253.91 217791.60 0.01 0.992 
memcm8 4892.27 401141.20 0.01 0.99 
memem8 -167.93 13631.79 -0.01 0.99 
memcm878 -4901.00 402153.80 -0.01 0.99 
memcm87 -4531.66 394922.70 -0.01 0.991 
memcm88 -4544.56 388574.60 -0.01 0.991 
memcm80 -5152.71 396416.50 -0.01 0.99 
memem878 172.73 14162.81 0.01 0.99 
memem87 268.68 21355.31 0.01 0.99 
memem80 153.21 12911.43 0.01 0.991 
pol4cxcr3 20.50 1873.06 0.01 0.991 
pol8x3r4ratio 18.85 1590.05 0.01 0.991 
act425lo 15.50 1380.24 0.01 0.991 
act4103hladr 567.84 51596.43 0.01 0.991 
act82571 446.11 51474.60 0.01 0.993 
act86971 -450.96 45674.70 -0.01 0.992 
D.9-4 Partial Dependence Analyses 
The PDP plots in Figure D-24 show that, with the exception of 
pol4th2, as all four remaining FC variables from stepwise GLM increased, 





Figure D-24. Partial Dependence Plots for FC Variables (Phenotype is Cancer) 
In particular, act4103hladr had the largest effect: the probability of 
having cancer ascended from approximately 0.054 to 0.079 as the 
standardized act4103hladr expression increased from around -1 to 1.7. On 
the contrary, the cancer probability decreased from around 0.063 to 0.056 
when standardized pol4th2 increased from about -1 to 0.  
Two different angles for the same 3D PDP with pol4th2, act825 and 
cancer probability are shown in Figure D-25. It was an estimated surface in 
which cancer probability grew with combination of decreasing pol4th2 and 






















Standardized FC Expression 








Figure D-25. 3D PDP with Two FC Variables                                                                               
Another issue was revisited: if the variables in the FC set are highly 
correlated, how would that affect the final results and interpretation? When 
using cancer as phenotype based on 071813 data set, the FC set includes 4 
highly correlated variables: one mother node (act4103) and three child nodes 
(act4103hladr, act410371, act425103). To examine the effect of variable 
correlation and robustness of PDP, 3 child variables from the FC set 
containing the parent act4103 were removed before the PDP of act4103 was 






Figure D-26. PDP of Act4103 Before and After Removing 3 Child Nodes 
The results in this section are all related to phenotype ‘Cancer’. In the 
next section, results of how the phenotypes ILD and Cancer are related in 
terms of GSEA will be presented.  
D.10 ILD – Cancer GSEA Intercomparison 
In order to examine inter-relationship between phenotype ILD and 
Cancer, results of GSEA inter-comparison of these two are shown here.  
Results in this section were based on data set IRIS071813. GSEA 
performance of the cancer FC set with ILD as the phenotype and vice-versa 
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were examined. The results were immediately obvious – GSEA performance 
in these experiments was not statistically significant. When ILD is 
phenotype using the cancer set, the ES is always smaller than 12 and very 
often below 10 regardless of FC set size (see Figure D-27). The associated 
estimated p-values are all above 0.3 which indicates a low level of statistical 
significance (show in Figure D-28). A similar situation occurs for cancer as 
the phenotype with the ILD FC set: no ES is above 12 and all estimated p-
values are over 0.3 (See Figures D-29 and D-30). The performance of these 
random walks was completely different from what was seen previously 
when using the same phenotype as the basis for the establishment of the 
ranked list and FC set. The motivation for performing these experiments was 
to examine whether overlapping FC sets exist for both ILD and Cancer 
phenotypes.  
Not only did these results indicate that there is little similarity shared 
between the two phenotypes in SSc patients, but they also highlight the 
specificity of different phenotypes. More detailed discussion can be found in 





Figure D-27. Enrichment Scores of GSEA for Different FC Set Sizes  
(CANCER Set – ILD is phenotype) 
         
 
Figure D-28. P-values associated with Enrichment Scores of GSEA for Different FC 
Set Sizes (CANCER Set – ILD is phenotype)                                                                                          



























































Figure D-29. Enrichment Scores of GSEA for Different FC Set Sizes 
(ILD Set –CANCER is phenotype) 
 
Figure D-30. P-values associated with Enrichment Scores of GSEA for Different FC 
Set Sizes (ILD Set –CANCER is phenotype) 







         
  
 















          
  





















In the following three sections, three different methods of determining 
FC sets were evaluated including biological information (§D.11), Student’s 
t-tests statistics (§D.12) and p-values from point-wise GLM (§D.13).  
D.11 Bio-informed FC Sets 
Another modification for creating FC sets abandoned the CRF-
informed VI list altogether and instead used two alternative sets (Table D-
20) comprised of possibly important markers that were identified by our 
medical colleagues: 
















Here is the random walk for the CD4 FC set (Figure D-31). No 
significant enrichment structure can be observed and the corresponding 
enrichment score is relatively low. 
 
 
Figure D-31. Random Walk that Results from CD4 Bio-informed FC Set  
Figures D-32 and D-33 show the corresponding GSEA results and 
significance levels for FC set sizes 3 to 11. No FC sets had statistically 
significant enrichment scores (p > 0.25). CD8 results were comparable. 
 
 







                
   













Figure D-33. P-values associated with Enrichment Scores of GSEA for Different FC  
Set Sizes (CD4 Bio-informed FC Set) 
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Figure D-32. Enrichment Scores of GSEA for Different FC Set Sizes (CD4 Bio-
informed FC Set) 


















Response is ILD  
FC Set Size 
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D.12  Student’s t-tests Based FC sets 
Two samples Student’s t-tests for act4103hladr and traff4ccr3 
expressions strongly suggested that there was differences between the cancer 
patients group and non-cancer patients group (at the 95% confidence level) 
(see §D.9-3). Motivated by these encouraging results, t statistics was used as 
the basis to construct FC sets. The followings are specific procedures of 
obtaining the Student’s t-tests based FC set. 
1. Perform t Tests for all 112 FC variables between cancer patients and non-
cancer group. 
2. Extract all the FC variables whose 95% C.I. excluded zero. Here, only 17 
FC variables remained. 
3. Ranked the 17 FC variables based on absolute signal-to-noise ratios. The 
signal here is the mean difference between cancer and non-cancer and the 
noise is the pooled sample variance. 
4. Used the ranked 17 FC variables as input for GSEA. 




Table D-21 Comparison between Ranked t-test Set and CRF VI List 
Ranked t-test Set Absolute Signal-to-Noise Ratio CRF  
act4103hladr 5.34 act4103hladr 
act410371 3.48 act410371 
mememra48 2.16 traff8cxcr5 
act425103 1.44 traff4ccr3 
act810369 1.12 act4103 
act4103 1.1 act425103 
memcm88 1.03 act82571 
act82571 0.99 act825 
traff4ccr3 0.89 pol4th2 
cd4cd8ratioLOG 0.87 memcm88 
mememra88 0.83 memem4 
act810371 0.7 traff8ccr10 
memcm87 0.7 
 memcm80 0.67 
 act469hladr 0.62 
 memcm40 0.55 
 memem47 0.55   
 
In Table D-21, the t-test set based on ranked absolute signal-to-noise 
ratio is presented, so is the CRF FC set. The ones highlighted in yellow are 
those appears in both FC sets. Shown in Figure D-34, the ES for t Test based 
FC sets achieved its maximum at FC set size 12. It can also be discerned that 
the ES did not increase monotonically. The estimated p-values for 
permutation tests were all smaller than 0.05 regardless of FC set size. This 





Figure D-34. Enrichment Scores of GSEA for Different Ranked t-tests FC Set Sizes 
(Cancer is Phenotype) 
 
 
Figure D-35. P-values associated with Enrichment Scores of GSEA for Different 
Ranked t-tests FC Set Sizes (Cancer is Phenotype) 
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D.13  p-value Based FC Sets 
D.13-1 Motivation and Procedure 
Inspired by the success achieved through drawing statistical inference 
from stepwise GLM (§C.5), FC sets based on the p-value associated with FC 
variable in GLM were constructed and used as input to GSEA. The analysis 
procedures are: 
• Construct a ranked FC list based on GLM p-value 
• Use FC sets as input for GSEA 
• Plot  ES vs. FC set size 
D.13-2 Phenotype is ILD 
We first used ILD as the phenotype for our p-value derived FC set 
analyses. Figure D-36 shows a comparison of our original and new lists for 
creating FC sets. The three FC variables in red are those appear both in the 
p-value based FC set and stepwise GLM. FC variables showing up in both 
CRF list and p-value based FC set are highlighted in yellow. Red slope lines 
were used to indicate FC variables that have high ranking in CRF list but 
lower ranking in p-value based FC list, while green is to the opposite. Gray 
lines indicate no ranking changes for certain variables such as pol8ccr5 and 
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memem4. The green horizontal line separates FC variable whose p-value is 
smaller than 0.05 from others.  
 
Figure D-36. Comparison between CRF Variable Importance List and P-value 











































































The FC set size experiment results are shown in Figure D-37. 
 
 
Figure D-37. Comparison between P-value based GSEA and CRF based GSEA in 
Enrichment Scores (Phenotype is ILD)














FC set size 59











When the phenotype is ILD, comparing the 27 most important FC 
identified by CRF with the sorted list of FC based on p-value from GLM, it 
can be found that 15 of FC variables appeared in both two lists. However, 
the order is completely different. There are only 10 FC were statistically 
significant at significance level 0.05 based on GLM. Several FC variables, 
such as memem8 and traff4cxcr6, were highly valued by CRF but not 
considered to be relatively important based on the above-mentioned p-values. 
On the other hand, 4 FC (act425hladr, act410371, memcm878 and memcm8) 
were included in the FC set but their p-values were not statistically 
significant. The 10 statistically significant FC variables based on GLM were 
all included in the FC set identified through CRF-GSEA algorithm. In 
addition to these 10, the FC set also contains variables that had large p-
values. This implies that the FC set based on CRF-GSEA algorithm does not 
simply include all the variables that have generally linear and significant 
relations with the response. It also contained variables that will contribute to 
the increase of ES, but whose association with ILD cannot be captured by 
GLM. 
These results suggest that FC variables appear consistently in FC sets 
constructed in different ways should be emphasized in that they may contain 
more useful information in explaining the response variables.   
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D.13-2-1  Comparison based on ROC 
I further compared our two methods for creating FC sets by 
examining ROC performance. The procedure is: 
• Using the 15 overlapped variables as the “base” group (Figure D-36, 
highlighted in yellow), calculate the in-sample ROC and Area Under 
Curve (AUC) associated with the model, denoted as AUC0 
• Add one of the remaining 12 variables, construct the model again with 
16 FC variables (15+1), record the AUC, denoted as AUCi 
• Calculate the difference between AUCi and AUC0 
• repeat for the other remaining variables  
When GLM was used to draw statistical inference (it also helps 
reduce the dimension of the data set in this case), the results shown in Table 




Table D-22 Increase in AUC associated with each FC using GLM 




Adding one of the following FC, the AUC becomes: 
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act4103hladr 0.803798   act4103hladr 0.000452 
It can be seen in Table D-22 that two of the variables have relatively 
larger contribution to AUC (highlighted in red) but the addition of 
traff4cxcr6 caused decrease in AUC (highlighted in blue). 
When the model used was CRF, we obtained: 
Table D-23 Increase in AUC associated with each FC using CRF 




Adding one of the following FC, the AUC becomes: 






































act4103hladr 0.939421   act4103hladr 0 
 
For both models, none of the 12 non-overlapped FC variables 
contributed substantially in terms of AUC. This is likely due to the result 
that AUC of the base model was already large, especially when CRF was 
used. The 12 non-overlapped FC variables selected by CRF were not 
selected because of their contribution to goodness-of-fit measured by AUC.  
D.13-3 Phenotype is Cancer 
The analyses including CRF-GSEA and point-wise GLM were 
repeated but with cancer as the phenotype. 
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D.13-3-1 Comparison between Ranked lists 
 
Figure D-38.  CRF Variable Importance List and P-value based FC List  
(Cancer is Phenotype)  
If “cancer” is the phenotype, almost all of the important FCs identified 
by CRF are statistically significant in the point-wise GLMs except one - 
memem4. Another FC, traff8cxcr4, had a low p-value but was not included 
in the FC set based on the CRF-GSEA approach. 11 out of 12 variables in 
the FC set were considered statistically significant by GLM, which suggests 
that their relations with “cancer” are identified by GLM. These results are 
consistent with the significant outputs of the stepwise GLM using 12 FC to 
















Figure D-39. Comparison between P-value based GSEA and CRF based GSEA in 
Enrichment Scores (Cancer  is Phenotype) 











D.14 Other Phenotypes 
The associations between SSc and various autoantibodies, especially 
Anti-topoisomerase I antibodies (ATA, or anti-Scl-70 antibodies) and anti-
centromere antibodies (ACA) have been discussed. Dick et al., (2002) found 
that “patients with both autoantibodies ATA and ACA often have diffuse 
scleroderma and show immunogenetic features of both antibody defined 
subsets of SSc”. Later, ACA was observed to be positive mostly in SSc 
patients who have CREST symptoms (Miyawaki, et al., 2005) and 
suggesting the occurrence of limited skin involvement (Castro, Jimenez, & 
Jefferson, 2010). Lota & Renzoni (2012) discovered that ATA and ACA 
were linked to pulmonary fibrosis and pulmonary hypertension respectively, 
and the presence of anti-Scl70 antibodies was believed to be indicator of 
higher risk for diffuse skin involvement and SSc lung disease (Castro, 
Jimenez, & Jefferson, 2010). Such connections may lead to new hypotheses 
on biological pathways and clinical relevance. Two clinical variables: 
Scl70_ab (Anti-topoisomerase) and ACA (Anti-Centromere Antibodies) 
were used as phenotype with FC as explanatory variables for CRF-GSEA 




When using Scl70_ab as phenotype variable, the ES peaked at 23.57 
which was associated with FC set size 38, and reach its minimum when FC 
set size is 60 (see Figure D-40).  With regard to p-values of permutation tests, 
they were all statistically significant when FC set size is smaller than 60 at 
significance level 0.05 (See Figure D-41).  
 






        
  
 
Figure D-40. Enrichment Scores for Different FC Set Sizes (Phenotype is Scl70_ab) 












Figure D-41. P-values associated with Enrichment Scores for Different FC Set Sizes 
(Phenotype is Scl70_ab) 
 
Figure D-42. Random Walk that Results from FC Set Comprised by Top 38 Most 
Important Variables (Phenotype is Scl70_ab) 
 

















       





























Thirty-eight FC covariates were used as input to fit a logistic binomial 
linear regression model with the two-directional stepwise variable selection 
algorithm estimating the binary outcome Scl_70ab (see Table D-24).  
Table D-24 Estimated Coefficients of Stepwise GLM (Phenotype is Scl70_ab) 
  Estimate Std. Error z value Pr(>|z|) 
(Intercept) -4.84 3.24 -1.5 1.34E-01 
act82571 -1.32 0.39 -3.35 8.15E-04 
memnaive4 -0.05 0.02 -2.96 3.12E-03 
pol4 0.15 0.07 2.07 3.83E-02 
cd4cd8ratioLOG -7.42 3.19 -2.33 2.00E-02 
pol8cxcr3 0.03 0.01 1.97 4.88E-02 
     
Residual deviance: 129.31  on 120  degrees of freedom 
 The Drop-in-Deviance test comparing the current stepwise GLM 
model with a null model (with intercept only) implies that these five 
variables are statistically significant (p-value = 2.71×10-6). The p-value of 
AUC = 0.786 










the goodness-of-fit Test was 0.265, suggesting that there is no evidence that 
the model is inadequate.  
Although a multivariate GLM will be used eventually for statistical 
inference, it is still interesting to examine which FC variable contributes 
most to explain the response. To evaluate how much each FC variable in the 
stepwise GLM contributes to goodness-of-fit, GLMs were fitted using only 
one FC at a time to estimate the response ILD (point-wise GLMs). Given 
that five FC variables were included in the stepwise GLM, there are five 
point-wise GLMs in total (Details in Table D-25). The corresponding AUC 
values of the in-sample ROC curves based on the point-wise GLMs are 
presented in Table D-26. Individually, the point-wise GLM with only 
act82571 fit the data set best in terms of AUC (=0.6757206). The fit was 
worst with pol4 (=0.5767738) among all the five point-wise GLMs. 
Table D-25 Details of Point-wise GLM (Phenotype is Scl70_ab) 
Pointwise GLM       
  Estimate Std. Error z value Pr(>|z|) 
(Intercept) 0.57 0.38 1.49 1.36E-01 
act82571 -1.08 0.33 -3.23 1.24E-03 
       
  Estimate Std. Error z value Pr(>|z|) 
(Intercept) 0.53 0.61 0.87 3.85E-01 
memnaive4 -0.02 0.01 -1.95 5.16E-02 
       
  Estimate Std. Error z value Pr(>|z|) 
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(Intercept) 1.11 1.07 1.04 3.01E-01 
pol4 -0.03 0.02 -1.63 1.03E-01 
       
  Estimate Std. Error z value Pr(>|z|) 
(Intercept) 0.25 0.41 0.60 5.51E-01 
cd4cd8ratioLOG -1.69 0.73 -2.30 2.12E-02 
       
  Estimate Std. Error z value Pr(>|z|) 
(Intercept) -1.79 0.74 -2.41 1.58E-02 
pol8cxcr3 0.02 0.01 1.65 9.90E-02 
 
Table D-26 AUC based on pointwise GLM using FC variable from the stepwise 
GLM (Phenotype is Scl70_ab) 





Next, the cumulative effects of FC variables in the GLM were 
examined. The five FC were ranked based on their point-wise AUC values. 
GLM models were fitted adding one FC at one time starting with act82571. 
The AUC of GLMs gradually increased from approximately 0.6757 to 0.786, 
shown in Table D-27. Details of these accumulative GLMs are presented in 






Table D-27 GLM with accumulative FC sets (Phenotype is Scl70_ab) 





Table D-28 Details of Accumulative GLMs (Phenotype is Scl70_ab) 
  Estimate Std. Error z value Pr(>|z|) 
(Intercept) 0.57 0.38 1.49 1.36E-01 
act82571 -1.08 0.33 -3.23 1.24E-03 
          
  Estimate Std. Error z value Pr(>|z|) 
(Intercept) 2.45 0.85 2.88 4.02E-03 
act82571 -1.23 0.36 -3.48 5.05E-04 
memnaive4 -0.04 0.01 -2.54 1.11E-02 
          
  Estimate Std. Error z value Pr(>|z|) 
(Intercept) 1.27 1.04 1.22 2.21E-01 
act82571 -1.26 0.37 -3.44 5.84E-04 
memnaive4 -0.04 0.02 -2.84 4.56E-03 
pol8cxcr3 0.03 0.01 2.03 4.21E-02 
          
  Estimate Std. Error z value Pr(>|z|) 
(Intercept) 1.56 1.08 1.44 1.50E-01 
act82571 -1.21 0.37 -3.29 9.91E-04 
memnaive4 -0.04 0.02 -2.48 1.32E-02 
pol8cxcr3 0.03 0.01 2.09 3.62E-02 
cd4cd8ratioLOG -1.16 0.84 -1.38 1.67E-01 
          
  Estimate Std. Error z value Pr(>|z|) 
(Intercept) -4.84 3.24 -1.50 1.34E-01 
act82571 -1.32 0.39 -3.35 8.15E-04 
memnaive4 -0.05 0.02 -2.96 3.12E-03 
pol8cxcr3 0.03 0.01 1.97 4.88E-02 
cd4cd8ratioLOG -7.42 3.19 -2.33 2.00E-02 





The analyses above were repeated with ACA as the phenotype. ES 
peaked at 24.9 which was associated with FC set size 6 and non-
monotonically decreased arriving at its minimum when FC set size is 79 (see 
Figure D-44).  The  p-values of permutation tests were smaller than 0.05 
when FC set size is smaller than 25, shown in Figure D-45.  
 
 
Figure D-44. Enrichment Scores of GSEA for Different FC Set Sizes 
(Phenotype is ACA) 
 





























Figure D-45. P-values associated with Enrichment Scores for Different FC Set Sizes 
(Phenotype is ACA) 
 
Figure D-46. Random Walk that Results from FC Set Comprised by Top 6 Most 
Important Variables (Phenotype is ACA) 


























aca - Random Walk with top 6 most important variab         





























Figure D-47. In-sample ROC Curve for CRF (Phenotype is ACA) 
GLM with logistic link function was fitted using input of 6 FC 
variables identified as the most important through CRF-GSEA algorithm to 
estimate the binary response ACA. Two-directional stepwise variable 
selection algorithm was then applied afterward. Only two of the six FCs 
remained in the final model (see details in Table D-29).  
Table D-29 Stepwise GLM with ACA as phenotype 
  Estimate Std. Error z value Pr(>|z|) 
(Intercept) -2.22 0.38 -5.83 5.40E-09 
pol8crth2 0.12 0.05 2.70 7.03E-03 
memem88 0.29 0.13 2.18 2.90E-02 
     
Residual deviance: 125.84  on 126  degrees of freedom 
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 The p-value of goodness-of-fit Test is 0.487, which suggests that there 
is no evidence that the model is inadequate. On the other hand, the p-value 
of Drop-in-Deviance test is 2.95E-05, which is significantly smaller than 
0.05. The null hypothesis that none of the two remaining FC variables 





In this chapter, the data mining methods used will be discussed (§E.1), 
followed by evaluation of the possibility of using other data mining models 
(§E.2). In section §E.3, different aspects of the Gene Set Enrichment 
Analysis (GSEA) algorithm will be focused, including potential 
improvements that can be made in the future. I will then discuss the 
randomized filter design procedure (§ E.4) and its potential clinical value in 
medical practice (§E.5).  
Biological meaning and interpretation of the defined FC set associated 
with ILD will be explored in Section §E.6. Issues regarding standardized 
Forced Vital Capacity (FVC) that was used to define ILD will be discussed 
in §E.7, and the importance of phenotype specificity will be highlighted in 
Section §E.8. This chapter ends with discussion on the two tools used to 
draw statistical inferences - stepwise GLM and Partial Dependence Plot 
(PDP) analysis.  
E.1 Data Mining 
The data mining techniques used (CART, RF, CRF and SVM) cannot 
outperform the mean-only model by a statistically significant amount in 
classifying the ILD status of SSc patients given their FC data as predictors. 
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However, their in-sample training performance showed that these models fit 
the data set well. CRF was eventually chosen based on its published 
performance with correlated predictor variables and testing with the IRIS 
data set.  More specifically, the permutation computing scheme for variable 
importance measure (VIMs) in CRF can provide a “more fair means of 
comparison that can help identify the truly relevant predictor variables” 
(Strobl et al., 2008).  
E.2 Other Data Mining Methods  
Characteristics of the data set of interest ultimately determine what 
type of models to be used. The IRIS data set used in this research is featured 
by ‘large P small N’ and highly correlated predictors issue. If the 
fundamental structure of the data set of interest is altered, especially the 
correlation structure of the FC variables, other tree-based models such as 
Random Forests, could possibly perform better. Moreover, other data mining 
methods such as GLM (that are not suitable for “large P small N” data sets) 
could prove effective provided that sample size is greatly expanded. But 
there also exist other approaches that have not yet been evaluated. For 
example, Bayesian confidence propagation neural network (BCPNN) was 
shown to be effective in classification in medical sciences (Orre et al., 2000; 
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Lisboa et al., 2003). Also, the selection of phenotype can significantly affect 
model performance. We discovered this when using pah_45 as phenotype. 
The resulting classification and GSEA performance was poor.  
In this work, CRF was chosen as a non-parametric method due to its 
strength in handling highly correlated predictor issue featuring the IRIS data 
set. CRF is recommended to be used in data sets with similar issues.  
E.3 Gene Set Enrichment Analysis 
The ES values associated with the FC sets formed from the group of 
variables at the top CRF variable importance list were consistently 
statistically significant based on the GSEA permutation test. The 
corresponding random walks were up-regulated. There exists a unique FC 
set size associated with an Enrichment Score supremum. Larger FC set sizes 
did not necessarily lead to greater enrichment scores. If all the variables in 
the FC set were highly correlated, the corresponding random walks would 
have even stronger enrichment and the estimated p-value of the GSEA test 
will be underestimated.  
As mentioned earlier, having determined the FC set, two directions 
analysis were performed – making predictions and drawing statistical 
inference. Understanding relationship between variables in the FC set will be 
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useful in drawing statistical inference. The best FC sets that we found 
consisted of variables from different panels, thus indirectly rejecting the 
scenario that all the variables in the FC set were highly correlated with each 
other (variables within the same panels have higher correlation than those 
from different panels). Occasionally, however, two or more variables in the 
best FC sets were highly correlated. In this case, confounder effects 
(multiple predictor variables and the response are pairwise correlated with 
each other) must be considered (Hennekens et al., 1987; Mickey & 
Greenland, 1989).  Several possible options are available to cope with 
confounder effects. The first option is to manually remove one of the 
predictor variables, which is imprudent in that the variable removed may 
have strong biological or clinical relevance. Another option is to combine 
predictor variables (forming a composite variable such as the ratio of two 
variables).  A common practice in epidemiology is to stratify the data by one 
of the confounders and then give an overall estimate combining individual 
strata-specific predictions (Hoggart et al., 2003). This method works well for 
categorical predictor variables, but certain thresholds must be established for 
continuous variables depending on the density and range of the variable.  
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E.3-1 GSEA Robustness 
In our “top-down” analyses (form FC sets beginning at the top of the 
ranked correlation list in GSEA), all random walks were up-regulated with 
strong enrichment scores. To test the robustness of this result, we instead 
constructed FC sets beginning at some variable considerably down the 
ranked list, and in some cases, formed FC sets beginning at the bottom of the 
ranked list. Results in Section §D.4-1 indicate that the regulation direction of 
the random walks were robust. Significant enrichment structure of random 
walk will always result in larger ES which was associated with statistically 
significant p-value in permutation test. GSEA performance was also robust 
to the number of shuffling in the permutation test (see Section §D.4-2).  
E.3-2 The GSEA Ranked List 
Thus far, the ranked lists of the GSEA test were based on sorted 
correlation coefficients. This is the original and most common approach 
(Subramanian et al., 2008), but others exist, for example, the absolute value 
of correlation coefficients could serve as the foundation of ranked list. It 
follows in that case that all random walks would be up-regulated (see 
Appendix §I.4). This could result from the situation that all the FCs with 
high correlation coefficient clustered toward the same area in the ranked list. 
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It is another way of constructing ranked list and could possibly be applied in 
condition that the sign of correlation coefficient does not matter.  
E.3-3 GSEA – FC Set Determination  
In the original genomics applications, gene sets for GSEA were 
formed through biological insight (our rough equivalent might be effector’s 
pathways). A reasonable alternative here is to define FC sets based on FC 
variables considered to be potentially important biomarkers. Two such FC 
sets (CD4-based and CD8-based) were created and tested through GSEA 
(see Section §D.11). Performance was poor when compared with the hybrid 
CRF-GSEA approach, but this exercise was very limited in scope.  
In the future, if certain pathway of autoimmune disorder is 
hypothesized, the group of variables involved in the pathway can become 
input of the GSEA-FC set and tested with permutation test, in order to 
examine the statistical significance level of the assumed pathway.  
E.3-4 GSEA – Permutation Test 
Gene Set Analysis (GSA) in general can be divided into two major 
schools based on the permutation schemes used in their statistical tests: class 
label randomization and gene randomization (Luo et al., 2009). The GSEA 
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algorithm in this research, SAFE (Barry et al., 2005) and SAM- CS (Dinu et 
al., 2007) belongs to the first category, while PAGE (Kim & Volsky, 2005), 
T-profiler (Boorsma et al., 2005) and Random Set (Newton et al., 2007) are 
classified as gene-randomization. An important factor in assessing the 
suitable approach is sample size. Our data set contains 119 patients. This 
sample size may not “allow rigorous evaluation of significance levels by 
permuting the class labels” (Subramanian et al., 2008), however, our results 
were indeed robust with respect to the number of permutations used to 
estimate p-values (see Section §D.4).  The alternative approach (gene-
randomization) is to permute FC variables, but this will lead to non-
conservative significance levels, i.e., smaller p-values resulting in more false 
positives, because this approach does not account for stimulus variable 
correlation (Subramanian et al., 2008).  
In sum, the GSEA algorithm used in this research can help determine 
a group of important variables with regard to certain phenotype variable. Its 
performance is robust. With certain modification in the three components of 
GSEA such as FC set and ranked list, this algorithm can be applied in many 
more fields along with other variable settings.   
135 
 
E.4 Randomized Filter Design 
Randomized filter design is a novel mathematical tool used for ILD 
classification. Its non-parametric nature allows application in many other 
settings.  In the current design, the predictor variables are continuous and the 
response binary, however, with fairly simple modification, response, for 
example, could be categorical.   
While training filters performed well when classifying the entire data 
set (Overall Misclassified Rate (OMR) = 0.1898), the added step of pre-
partitioning patients using CART (and finding best training filters specific to 
each CART group) significantly improved filter performance. The splitting 
criterion used in CART appears to be a good starting point for identifying 
subpopulation of SSc patients. Our training filter experiments consistently 
resulted in best filters having three to six components with five most often. 
We currently have no mathematical or biological explanation why this 
should be the case.  
Predictive accuracy of this screening tool was promising in this study. 
However, its computation was rather expensive. It will be rather useful if 




E.5 Clinical Value of Screening Tool  
Validation was successful (Section §D.6) with a correct classification 
rate of 82.5% for the entire validation data set (40 patients), increasing to 
95% with CART pre-partitioning. There exists a reasonable balance between 
training and validation error. Given FC data as input, the prediction of 
patient ILD status with our filter approach is essentially instantaneous and 
can be accomplished through a variety of software implementations. 
Ultimately this instrument should facilitate a refined stratification of SSc 
patients into clinically relevant subsets at the time of diagnosis and 
subsequently during the course of the disease, preventing bad outcomes from 
disease progression or unnecessary treatment side effects. This role could 
involve a scenario in which an SSc patient passes the presumptive test for 
ILD, but the filter indicates that their flow cytometry (FC) profile is 
consistent with ILD. In such a case, a physician might: 1) increase frequency 
of testing to detect early development of ILD; 2) implement more 
sophisticated diagnostic procedures (e.g., high resolution chest CT scan) to 
confirm the presence of ILD; and 3) consider prophylactic disease 
modifying treatments (e.g., cyclophosphamide, corticosteroids, interferons 
(White, 2003)).  
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We would expect that as more data becomes available, filter 
performance will continue to improve. This suggests another potentially 
important role for our approach in better understanding the progression of 
disease. We posit the scenario in which FC profile characteristics may 
change with disease progression and that these changes could be captured – 
reflected in changes in filter design and performance. Procedurally, we 
contemplate a procedure in which certain FC variables and their expressions 
are used as a basis for partitioning patients into disease progression states, 
with corresponding state-specific filter designs.  
The potential clinical value of the screening tool is encouraging.  
E.6 Biological Interpretation  
In FC27 (see Section §D.3, Table D-4), the two FC variables 
(pol8ccr5cxcr3neg, pol8ccr5cxcr3) identify Type 1 helper (Th1) polarized 
CD8 T cells. Informed by our medical colleagues, the first (lacking CXCR3) 
is “protective”; the second (CXCR3) is a “risk factor” for ILD. CXCR3 is a 
chemokine receptor which has been shown to direct inflammatory cells 
inside target tissue and drives acute inflammation (synovial tissue in 
rheumatoid arthritis, liver in autoimmune hepatitis, etc.). The variables 
memem8, mememra87, memcm878 and memcm4 belong to the T cell 
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memory subset. It appears that ILD status is associated with a shift of the 
CD8 T cells towards the activated effector memory/terminally differentiated 
state. This is in keeping with the pro-inflammatory polarized status observed. 
E.7 Issues Regarding FVCstpp   
FVCstpp is imprecise (e.g., poorly performed maneuvers) and 
uncertain (variable from test to test) (Alhamad et al., 2001; Enright, 2003; 
Hegewald & Crapo, 2010; Miller, 2005; Pierce, 2005; Petty & Enright, 2003; 
Hankinson, 1999) which presents several questions involving: (1) the 
accuracy of the current FVCstpp cutoff in accurately assessing ILD status; (2) 
the effect of the cutoff in filter performance; and (3) a corollary, whether the 
patients that are misclassified in training and validation have FVCstpp 
measurements in the so-called “gray area”.  Further to (3) Table E-1 shows 
FVCstpp values from the IRIS data set that are close to the ILD cutoff (80 
+/- 5%). The results are inconclusive: nine patients in this group of twenty-
two are among the misclassified patients in training and validation. The 
entries shaded in blue are training misclassifications; those in red are for 



















Issue (1) points to the need for High Resolution Computing Tomography 
(HRCT) for interstitial lung disease (ILD) confirmation (Moore et al., 2013; 
Pandey et al., 2010; Zompatori et al., 2013). 
E.8 Phenotype Specificity (ILD vs. Cancer) 
Using different phenotypes as response variable resulted in distinctive 
outcomes including the best FC sets, direction of random walk, ES and 
model performance. In this study, the results associated with “cancer” as 
phenotype were found to be more striking than other phenotypes (see 
Section §D.9).  
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GSEA performance of the cancer FC set with ILD as the phenotype 
and vice-versa were examined. The results were not statistically significant – 
small ES and large estimated p-value. Although all the patients of interest 
were diagnosed as having SSc, yet the two phenotypes (cancer and ILD) are 
discovered to be related to different biomarkers and therefore distinct FC 
expressions. For example, as mentioned in section A.2 Systemic Scleorsis, 
previous studies have shown that increased frequency of circulating T cells 
exhibiting a “polarized” phenotype –the Polarization panel in the IRIS data 
set- are significantly associated in SSc patients with the presence of 
pulmonary fibrosis and lung disease progression (Boin et al 2008; Truchetet 
et al. 2010). However, it remains unknown whether such association still 
holds when the phenotype is cancer from the perspective of medical sciences.   
Regarding methodology, the inferior performance of the ILD-Cancer 
GSEA intercomparison experiments greatly suggests that the two 
components of GSEA algorithm (ranked list and FC set) should be always 
associated with the same phenotype in order to obtain reasonable and 
interpretable results, unless there is a significant number of overlapping 
“genes” across different sets. Subramanian et al. (2008) performed similar 
experiments using the Boston gene set in the Michigan lung cancer data sets, 
and the Michigan gene set in the Boston data set, in an attempt to draw 
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biological insight by examining overlapping genes. In our research, a similar 
analysis indicates that very few FC variables were overlapping between the 
ILD set and Cancer set (see Section §D.10).  
E.9 Statistical Inference 
E.9-1 Stepwise GLM 
When the phenotype was ILD, the p-value of the Goodness-of-fit Test 
for the stepwise GLM was approximately 0.15, which suggests that there 
was no evidence that the model is inadequate. However, this p-value was not 
large enough (close to 1) to be considered as statistically significant, 
therefore statistical inference from this model should be made cautiously, 
particularly the interpretation of the coefficients of each FC in the model. 
This under-fit eventually becomes one of the reasons why the outputs of this 
model are inconsistent with those of the Partial Dependence Plot for CRF 
which will be discussed in the next section. However, several Drop-in-
Deviance Tests regarding this stepwise GLM strongly suggest that the six 
FC variables and the three clinical variables (type, scl70_ab, dd1symptom_y) 
are of significant importance in estimating the response variable ILD. In 
addition, none of the four diagnostic statistics indicate that there were 
142 
 
isolated cases that have either high leverages or outliers regarding the fitted 
GLM.  
If using cancer as the phenotype, the stepwise GLM fitted the data set 
very well (p-value of the Goodness-of-fit Test was almost 1). All 4 FC 
variables were statistically significant at 5% level. Among these variables, 
pol4th2, or CD3+/CD4+/CD8-/CXCR3-/CCR4+/CCR6-, was negatively 
associated with the odds of having cancer and especially important in 
differentiating patients with cancer from those without. The other three 
variables are positively associated with the odds of having cancer, among 
which variable act4103hladr had the strongest association. These results 
were consistent with the PDP outputs below. In addition, based on Cook’s 
distance, standardized residuals and Studentized residuals, two patients 
(ID:2202, 3083) were identified as isolated observations. These two cases 
heavily influenced the coefficients of variable act4103hladr (from 3.05 to 
5.52). Lastly, without CRF-GSEA procedure, the fitted stepwise GLM based 
on the full data set did not fit the data set well – none of the remaining FC 
variables were statistically significant.  
GLM with a logistic link function assuming binomial distribution of 
the responses followed by stepwise algorithm has been widely used in 
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explaining dichotomous response variable using multiple continuous or 
categorical predictor variables (Hirzel et al., 2001; Ethier et al., 2008; 
Karlsson et al., 2010;). It was used in this research after the data dimension 
was reduced and it turned out to be rather useful in terms of drawing 
statistical inferences.  
Statistical inferences directly drawn from the stepwise GLM regarding 
coefficients of the FC variables should be of caution. It is true that stepwise 
GLM may have certain drawbacks such as potential exclusion of important 
variables but inclusion of noise variables (Derksen and Keselman, 1992) and 
Type 1 error inflation issues (Mundry & Nunn, 2009). However, in this work, 
the starting GLM was a full model, i.e., including all predictor variables at 
the beginning, therefore no exclusion of variables was made. Also, the 
statistical significance of the group of important variables was determined 
by the Drop-in-Deviance tests, instead of simply relying on significance 
level of Z-score Wald tests on an individual basis. The p-values of Z-score 
Wald tests were not used as the basis of determining statistical significance 
of multiple variables as a group, because these individual p-values tend to 
change when the number of input variables varies. Note that before the GLM 
had been fitted, a GSEA test was performed to guarantee that the group of 
FC variables was statistically significant as an entity. Lastly, the intention of 
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applying stepwise GLM is to present one possible approach for extending 
the results from CRF-GSEA and hopefully shed lights on future medical 
research direction.  
One interesting finding was that without CRF-GSEA procedure, the 
stepwise GLM based on original full data set had low level of goodness-of-
fit; but with CRF-GSEA, its fit was considerably improved. This result may 
originate from that stepwise GLM itself was insufficient to identify 
important variables, especially when the data set suffers from “Large P small 
N” issue. Another related explanation could be the predictor correlation 
issue which in this case was handled to some degree by the hypothesis 
testing structure in CRF.  
E.9-2 Partial Dependence Analysis  
For ILD as phenotype, as the values of FC variables memcm878 and 
memcm4 increased, the probability of having ILD became larger. The 
remaining four FC variables had the opposite trend with regard to the 
association with the probability of having ILD. Comparing these results with 
the estimated coefficients of stepwise GLM, only a moderate level of 
consistency can be found regarding whether the FC variables exert positive 
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or negative impacts on the probability of having ILD. The most likely reason 
for this result is that stepwise GLM did not fit the data set very well. 
When cancer was the phenotype, as three of four FC variables 
increased, the estimated probability of having cancer in SSc patients also 
increased when using PDP.  The exception was pol4th2. The 3D PDP with 
pol4th2, act825 and cancer probability indicated that cancer probability grew 
with a combination of decreasing pol4th2 and increasing act825. These PDP 
results are consistent with the stepwise GLM outputs. These PDP results 
strongly suggest that act4103hladr, traff4ccr3, act825 are positively 
associated with the probability of having cancer; its association with pol4th2 
is negative.  
Partial dependence plots are useful in diagnosing the dependence of a 
response variable on the joint values of stimulus variables (Hastie et al., 
2009). However, visualization with high dimensions can be difficult to 
visualize and interpret. PDP results are useful for yielding insights into the 
marginal effect of individual covariates, especially when the model of 




1. The combination of CRF and GSEA algorithm can determine 
statistically significant FC sets associated with phenotypes ILD and cancer. 
This approach is robust in terms of statistical significance of the GSEA 
permutation test.  
2. Randomized filter design is an effective approach in differentiating 
patients with ILD from those without.  
3. Stepwise GLM in conjunction with Partial Dependence Plots could 
be useful in drawing statistical inference from the outputs of CRF-GSEA 
algorithm.  
4. The specificity of phenotypes will directly impact the performance 
of GSEA algorithm.   
5. The construction of FC sets can be based on different methods.  
6. When ILD is the phenotype, variables included in p-value based FC 
set are the most important ones for the following reasons: a. results based on 
CRF VI list, filter set list and p-value based FC set were more statistically 
significant than bio-informed FC set; b. all the variables included in the p-
value based FC set were included in CRF VI list and filter set list. These 
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variables are: pol8ccr5, memnaive4, memem4, pol8ccr5cxcr3, pol4ccr6, 
pol8ccr5cxcr3neg, act425lo, act425tot, mememra87, act4103, memem48, 
mememra478, mememra4, act425103 and memem478. 
If Cancer is the phenotype, the variables listed below are attached 
with more importance because they showed up in CRF VI list, p-value based 
FC set and T Test based FC set. These variables are: act4103hladr, 
act410371, traff4ccr3, act4103, act425103, act82571 and memcm88. 
Details of the best FC set identified by different methods can be found 




G. FUTURE RESEARCH 
 The major focus thus far has been on ILD and cancer, driven by the 
seriousness of these diseases, but there are other phenotypes associated with 
SSc that too have important clinical outcomes, for example, elevated Right 
Ventricular Systolic Pressure (rsvp) and depressed Spirometry Diffusion 
Capacity (dlco). Principal Components Analysis was eventually not used 
because of the limitation of interpretability. Other factor analysis such as 
Sparse Factor Analysis (SPA) (Carvalho et al., 2008; Engelhardt & Stephens, 
2010) that may be able to overcome the interpretability issue can be 
explored.  
Data mining approaches followed by GSEA can be applied to these 
phenotypes. For those phenotypes that share common or highly relevant 
biological pathways, a GSEA intercomparison could be used to examine the 
overlaps in order to yield biological insights. Other data mining methods 
could be evaluated in addition to the five (CART, RF, CRF, SVM, GLM) we 
considered. Different antibodies associated with SSc can also be used as the 
phenotype. More ways of determining significant FC sets can be explored.  
In the future, if certain pathway of autoimmune disorder is 
hypothesized, the group of variables involved in the pathway can become 
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input of the GSEA-FC set and tested with permutation test, in order to 
examine the statistical significance level of the assumed pathway.  
The randomized screening tool can be modified such that less 
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I.1 Appendix - FC Variable Panels 
Figure I-1. Hierachical Structure of Activation Panel 
 









I.2 Appendix FC sets identified by CRF-GSEA algorithm 
Table I-1 FC sets identified by CRF-GSEA algorithm (Phenotype is ILD) 
CRF FC Set Filter Set Bioinformed FC Set  P-value Based FC Set 
pol8ccr5 act4103 pol4th1 pol8ccr5 
pol8ccr5cxcr3neg pol8ccr5 pol4th2 memnaive4 
memem4 act425tot pol4th17 memem4 
pol8ccr5cxcr3 act425lo pol4th1th17 pol8ccr5cxcr3 
act4103 pol8th17 act425lo pol8ccr5cxcr3neg 
act425lo mememra4 act425hi act425lo 
memem478 act8103 act4dr act425tot 
act8103 pol8ccr5cxcr3neg traff4ccr10 pol4ccr6 
memem8 pol8ccr4 traff4cxcr6 mememra87 
mememra87 act425103 memnaive4 act4103 
act425103 pol8th1th2ratio mem4cmefratio     memem48 
traff4cxcr6 act810371 act8103 mememra478 
memnaive4 memem4 pol8cxcr3 mememra4 
act425tot pol8x3r4ratio pol8ccr4 act425103 
memcm878 memem478 pol8ccr6 memem478 
act410371 mememra4k act8dr   
pol4ccr6 pol8th2 traff8cxcr6   
memem878 memem878 traff8ccr10   
mememra478 mememra478 memnaive8   
memcm4 memem48 mem8cmefratio    
memcm478 act4dr mem8ememraratio             
traff8cxcr4 memem8 memcd8k   
mememra4 memcm478     
act425hladr memcm4k     
memcm8 act8dr     
act4103hladr traff4ccr3     





Table I-2 FC sets identified by CRF-GSEA algorithm (Phenotype is Cancer) 
CRF FC Set p-value Based FC Set t-tests Based FC Set 
act4103hladr act4103hladr act4103hladr 
act410371 act82571 act410371 
traff8cxcr5 traff4ccr3 mememra48 
traff4ccr3 act410371 act425103 
act4103 act4103 act810369 
act425103 act425103 act4103 
act82571 traff8cxcr5 memcm88 
act825 act825 act82571 
pol4th2 memcm88 traff4ccr3 
memcm88 traff8cxcr4 cd4cd8ratioLOG 
memem4 pol4th2 mememra88 
traff8ccr10 traff8ccr10 act810371 
    memcm87 
    memcm80 
    act469hladr 
    memcm40 













































Table I-4 FC sets identified by CRF-GSEA algorithm (Phenotype is ACA) 










I.3 Appendix - PCA Loading Matrix 
Table I-5 PCA Loading Matrix for all FC Variables (First 10 Principal Components) 
 
Comp.1 Comp.2 Comp.3 Comp.4 Comp.5 Comp.6 Comp.7 Comp.8 Comp.9 Comp.10 
pol4 -0.114 0.134 -0.128 0.015 0.041 0.115 -0.098 0.152 -0.055 0.019 
pol8 0.076 -0.131 0.139 -0.034 -0.081 -0.142 0.056 -0.166 0.037 -0.055 
memnaive4 -0.193 0.027 0.031 0.092 -0.132 0.052 -0.018 0.161 -0.106 -0.005 
memcm4 0.151 -0.057 -0.046 -0.210 -0.012 -0.041 -0.035 -0.092 0.132 -0.111 
mememra4 0.050 0.014 0.025 0.171 0.142 0.129 0.019 -0.119 -0.020 0.214 
memem4 0.101 0.038 0.001 0.112 0.220 -0.072 0.076 -0.122 -0.011 0.114 
mememra478 -0.056 0.026 -0.004 0.158 0.098 0.026 0.000 -0.090 0.011 0.193 
mememra47 0.087 0.068 0.024 0.026 0.105 0.009 0.030 -0.076 -0.072 -0.008 
mememra48 0.077 0.012 0.044 0.089 0.076 0.098 0.065 0.014 0.069 0.216 
mememra40 0.149 -0.018 0.049 0.076 0.101 0.181 0.021 -0.082 -0.055 0.098 
memcm478 0.141 -0.055 -0.056 -0.203 -0.028 -0.046 -0.054 -0.100 0.128 -0.142 
memcm47 -0.006 -0.008 0.000 -0.060 0.071 -0.086 0.124 0.018 -0.064 0.115 
memcm48 0.096 -0.025 0.033 -0.120 0.069 0.034 0.069 0.023 0.102 0.135 
memcm40 0.116 -0.054 0.061 0.053 0.061 0.034 0.079 -0.037 -0.069 -0.007 
memem478 0.021 0.056 -0.063 0.125 0.159 -0.104 0.026 -0.129 0.037 0.114 
memem47 0.096 0.016 0.052 -0.024 0.106 -0.098 0.109 -0.064 0.034 0.019 
memem48 0.106 0.035 0.040 0.008 0.205 -0.044 0.142 -0.020 0.068 0.135 
memem40 0.155 -0.040 0.108 0.038 0.121 0.060 0.047 -0.046 -0.157 -0.024 
memcm4k 0.172 -0.041 0.108 0.049 0.144 0.101 0.051 -0.048 -0.135 0.027 
mememra4k 0.140 -0.011 0.057 0.066 0.103 0.171 0.004 -0.079 -0.070 0.094 
memem4k 0.156 -0.033 0.106 0.030 0.142 0.059 0.061 -0.034 -0.149 -0.015 
memnaive8 -0.220 -0.026 -0.019 0.005 -0.087 0.036 0.032 -0.207 -0.029 0.012 
memcm8 0.083 0.133 -0.129 -0.213 0.108 0.101 0.008 0.004 0.034 -0.047 
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mememra8 0.124 -0.060 0.190 0.089 -0.023 0.062 -0.050 0.076 0.067 0.092 
memem8 0.157 0.006 -0.059 0.050 0.077 -0.172 -0.008 0.229 -0.036 -0.073 
mememra878 -0.025 0.059 -0.012 0.139 0.042 -0.056 -0.067 -0.054 0.093 0.202 
mememra87 0.060 -0.008 0.117 0.014 -0.010 -0.025 -0.103 0.048 0.117 -0.004 
mememra88 0.095 0.036 0.063 0.013 0.052 0.012 0.019 0.034 0.087 0.175 
mememra80 0.129 -0.081 0.188 0.067 -0.035 0.089 -0.018 0.085 0.025 0.056 
memcm878 0.078 0.129 -0.130 -0.216 0.104 0.095 0.011 0.004 0.040 -0.050 
memcm87 0.058 0.105 -0.096 -0.030 0.074 0.105 -0.077 -0.007 0.004 -0.012 
memcm88 0.112 0.144 -0.077 -0.158 0.108 0.091 0.005 0.004 -0.034 0.012 
memcm80 0.101 0.051 0.007 0.021 0.107 0.159 -0.018 0.009 -0.118 0.025 
memem878 0.092 0.051 -0.176 0.048 0.036 -0.205 -0.047 0.123 0.056 0.044 
memem87 0.100 -0.010 0.051 0.007 0.021 -0.089 0.004 0.105 0.023 -0.169 
memem88 0.114 0.112 -0.083 -0.022 0.087 -0.105 -0.001 0.062 0.034 0.043 
memem80 0.107 -0.072 0.108 0.032 0.064 -0.004 0.040 0.202 -0.141 -0.136 
memcd8k 0.147 -0.120 0.159 0.049 -0.012 0.059 -0.037 0.176 -0.041 -0.077 
mememra8k 0.127 -0.099 0.168 0.055 -0.048 0.105 -0.075 0.087 0.033 0.031 
memem8k 0.110 -0.099 0.088 0.022 0.032 -0.016 0.022 0.205 -0.105 -0.170 
pol4ccr4 0.109 0.167 0.026 0.096 -0.077 -0.150 0.032 -0.143 -0.030 -0.115 
pol4ccr5 0.013 -0.025 -0.060 0.008 0.053 -0.204 0.118 -0.057 -0.268 0.089 
pol4ccr6 0.128 -0.092 -0.083 0.006 -0.011 -0.090 -0.095 -0.196 -0.062 -0.105 
pol4crth2 0.109 -0.047 -0.013 -0.044 -0.064 -0.122 0.063 -0.109 0.007 -0.054 
pol4cxcr3 0.060 -0.115 -0.079 -0.156 0.155 -0.121 0.139 -0.016 0.113 -0.016 
pol4ccr5cxcr3 -0.007 -0.067 -0.086 -0.052 0.089 -0.177 0.165 0.025 -0.177 0.102 
pol4ccr5cxcr3neg 0.037 0.045 -0.011 0.078 -0.016 -0.159 -0.004 -0.132 -0.269 0.038 
pol4ccr5negcxcr3 0.071 -0.102 -0.053 -0.155 0.138 -0.062 0.088 -0.028 0.202 -0.061 
pol4th1 0.016 -0.138 -0.059 -0.183 0.175 -0.027 0.114 0.077 0.135 0.065 
pol4th1th17 0.021 -0.170 -0.107 -0.081 0.059 -0.093 0.012 -0.078 0.010 -0.075 
pol4th2 0.048 0.221 0.061 0.113 -0.109 -0.111 0.060 -0.066 0.002 -0.065 
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pol4th17 0.147 0.005 -0.022 0.064 -0.048 -0.075 -0.136 -0.199 -0.120 -0.122 
pol8ccr4 0.065 0.234 0.030 0.051 -0.064 -0.124 0.075 -0.038 -0.018 -0.109 
pol8ccr5 0.078 -0.048 -0.150 0.082 -0.019 -0.185 -0.064 0.220 -0.073 0.067 
pol8ccr6 0.087 0.032 -0.181 0.037 -0.034 -0.143 -0.156 0.078 -0.040 0.039 
pol8crth2 0.107 0.117 -0.039 -0.138 0.034 0.004 0.051 -0.029 -0.111 -0.089 
pol8cxcr3 -0.150 -0.104 -0.111 0.054 0.083 -0.052 0.178 -0.057 -0.018 -0.092 
pol8ccr5cxcr3 0.021 -0.111 -0.132 0.035 0.032 -0.121 0.083 0.193 -0.092 0.009 
pol8ccr5cxcr3neg 0.096 0.043 -0.093 0.089 -0.061 -0.158 -0.183 0.137 -0.017 0.093 
pol8ccr5negcxcr3 -0.172 -0.067 -0.066 0.044 0.077 -0.006 0.158 -0.141 0.018 -0.103 
pol8th1 -0.152 -0.195 -0.103 -0.010 0.109 0.041 0.086 -0.042 -0.030 -0.001 
pol8th1th17 -0.024 -0.082 -0.172 0.009 0.050 -0.049 -0.104 0.064 0.016 0.035 
pol8th2 0.092 0.254 0.075 -0.023 -0.062 -0.052 -0.011 -0.039 -0.026 -0.033 
pol8th17 0.115 0.108 -0.102 -0.013 -0.022 -0.076 -0.141 0.001 -0.128 -0.001 
cd4cd8ratioLOG -0.089 0.144 -0.129 0.020 0.073 0.136 -0.074 0.154 -0.036 0.041 
pol8th1th2ratio -0.128 -0.250 -0.089 0.000 0.078 0.058 0.013 -0.017 -0.011 0.053 
pol8x3r4ratio -0.121 -0.149 -0.045 -0.038 0.055 0.062 -0.068 -0.072 -0.036 0.023 
cd8r5th2ratio -0.012 -0.074 -0.054 0.080 0.006 -0.101 -0.085 0.177 -0.029 0.082 
cd4r5th2ratio -0.062 0.031 -0.032 0.041 0.100 -0.094 0.017 0.036 -0.184 0.114 
act425hi 0.018 -0.034 0.011 -0.029 -0.082 -0.107 0.023 -0.095 0.027 0.060 
act425lo 0.044 -0.013 -0.006 0.075 -0.092 0.047 -0.154 -0.190 -0.017 -0.047 
act425tot 0.047 -0.019 -0.004 0.071 -0.105 0.030 -0.151 -0.206 -0.012 -0.037 
act469 0.066 -0.005 -0.124 0.226 -0.068 0.073 0.193 0.005 0.121 -0.094 
act471 0.032 -0.123 -0.101 0.052 -0.083 -0.011 -0.025 -0.080 -0.178 0.036 
act4103 0.123 -0.115 -0.014 -0.016 -0.152 -0.036 -0.006 -0.045 0.090 0.192 
act4dr 0.028 0.092 0.045 -0.147 -0.192 0.058 0.180 0.027 -0.051 0.142 
act825 0.116 0.150 -0.090 -0.150 0.016 0.083 0.005 -0.052 -0.053 -0.015 
act869 0.047 0.037 -0.156 0.201 -0.016 0.051 0.138 0.053 0.066 -0.154 
act871 0.083 -0.111 -0.128 0.030 -0.038 0.176 0.070 -0.009 -0.073 -0.016 
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act8103 0.041 0.075 -0.151 -0.003 0.047 0.055 -0.174 0.025 0.127 0.121 
act8dr -0.007 0.075 0.012 -0.142 -0.167 0.104 0.167 0.048 -0.145 0.083 
act42569 0.079 -0.016 -0.124 0.222 -0.087 0.082 0.166 -0.029 0.107 -0.085 
act42571 0.030 -0.130 -0.099 0.063 -0.091 -0.002 -0.068 -0.124 -0.184 0.030 
act425103 0.110 -0.105 -0.029 -0.012 -0.161 -0.043 -0.025 -0.093 0.068 0.167 
act425hladr 0.032 0.081 0.038 -0.126 -0.211 0.067 0.140 0.002 -0.052 0.118 
act46971 0.086 -0.023 -0.153 0.169 -0.124 0.036 0.161 0.025 0.106 -0.041 
act469hladr 0.084 -0.009 -0.108 0.078 -0.178 0.077 0.168 0.048 0.124 0.091 
act410371 0.095 -0.171 -0.077 -0.007 -0.147 -0.022 -0.027 -0.003 0.054 0.153 
act4103hladr 0.107 -0.078 -0.057 -0.037 -0.175 -0.032 0.017 -0.020 0.117 0.167 
act471hladr 0.058 -0.050 -0.082 -0.069 -0.218 -0.006 0.130 0.049 -0.115 0.187 
act82571 0.093 -0.007 -0.202 -0.092 -0.020 0.147 -0.017 0.008 -0.116 -0.006 
act86925 0.047 0.118 -0.149 0.065 0.020 0.101 0.053 -0.046 -0.016 -0.068 
act86971 0.096 -0.017 -0.145 0.153 -0.022 0.115 0.186 0.006 0.054 -0.096 
act869hladr 0.037 0.038 -0.114 0.107 -0.119 0.088 0.231 0.091 0.016 -0.111 
act810325 0.040 0.110 -0.153 0.020 0.025 0.055 -0.154 -0.047 0.077 0.093 
act810369 0.055 0.028 -0.164 0.121 0.002 0.094 0.005 -0.044 0.135 -0.056 
act8103hladr -0.016 0.084 -0.118 0.070 0.023 -0.009 -0.025 -0.076 -0.009 0.122 
act810371 0.074 -0.065 -0.155 -0.004 0.007 0.098 -0.172 -0.018 0.063 0.050 
act8hladr25 0.022 0.120 -0.045 -0.169 -0.095 0.066 0.114 -0.022 -0.087 0.057 
act8hladr71 0.001 -0.098 -0.091 -0.073 -0.092 0.099 0.048 0.016 -0.221 -0.026 
traff4ccr2 0.038 -0.025 0.040 -0.103 -0.115 -0.083 0.083 0.005 -0.025 0.104 
traff4ccr3 0.137 -0.069 0.004 -0.062 -0.127 0.027 -0.089 -0.027 0.059 -0.054 
traff4cxcr4 -0.081 0.163 0.061 0.036 -0.022 -0.152 0.053 0.031 0.092 0.048 
traff4cxcr5 0.087 -0.130 -0.045 0.095 0.018 -0.035 -0.119 -0.055 -0.001 -0.131 
traff4cxcr6 0.017 0.040 0.076 -0.058 -0.067 -0.040 0.028 -0.005 0.106 0.027 
traff8ccr2 0.022 0.024 -0.014 -0.048 -0.087 -0.014 0.046 0.032 -0.146 0.066 
traff8ccr3 -0.001 -0.020 -0.067 -0.105 0.000 0.127 -0.113 0.005 -0.086 -0.040 
196 
 
traff8cxcr4 -0.149 0.139 -0.033 0.007 0.030 -0.125 0.096 -0.137 0.048 0.022 
traff8cxcr5 -0.004 -0.051 -0.122 -0.057 -0.019 0.102 -0.069 -0.058 -0.147 -0.042 
traff8cxcr6 0.050 0.018 0.015 0.040 0.008 -0.003 0.103 0.099 0.023 -0.118 
traff4ccr10 0.049 -0.013 -0.022 -0.054 -0.048 -0.081 0.049 0.014 -0.005 0.091 
traff8ccr10 0.029 -0.041 -0.062 -0.055 -0.027 -0.019 -0.002 0.062 -0.001 0.085 
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